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1.1. Synaptic transmission 
Synaptic transmission is an essential process of communication for all neuronal 
processes in the brain. Human brain performs several functions such as conduction, 
computation, storage and modulation of electrical information. These functions are 
mediated by highly differentiated cells of the brain- neurons. Mammalian brain 
consists of billions of neurons organized into a sophisticated network of connectivity. 
The connectivity among neurons is maintained through the intercellular connections 
called synapses.  
Synapses are asymmetric intercellular junctions that aid in the transmission of 
information either through chemical (neurotransmitter) or electrical signals. Each 
synapse comprises of two functional units: a presynaptic compartment consisting of 
large number of proteins involved in synaptic vesicle release machinery and a 
postsynaptic compartment that receives the transmitter and propagates the signal. 
Electrical synapses are characterized by 2-4nm area of apposition and chemical 
synapses by a distance of 20-40nm between pre- and post-synaptic membranes 
(Hormuzdi et al., 2004). The transmission of information occurs through gap 
junction channels by a passive flow of current between adjacent cells. Chemical 
synapses communicate through the release of neurotransmitter from presynaptic to 
postsynaptic neuron upon arrival of an action potential. 
1.2. Chemical synapses 
Signal transduction in the mammalian brain happens mainly through chemical 
synapses, where the synaptic transmission occurs mainly by Ca2+ triggered release 
of neurotransmitter. Upon arrival of an action potential in the presynaptic terminal, 
Ca2+ enters through the voltage gated calcium channels triggering the Ca2+ 
dependent exocytosis of synaptic vesicles and ultimately the release of 
neurotransmitter into the synaptic cleft. The released neurotransmitters from the 






membrane leading to the translation of chemical signal back into an electrical 
signal.  Exocytosis of synaptic vesicles occurs at a specialized area of the plasma 
membrane in the presynaptic terminal called the active zone (AZ). 
1.3. Synaptic vesicle cycle 
The Ca2+-triggered exocytotic release of neurotransmitter from synaptic vesicles 
includes a series of cyclic events in a process known as synaptic vesicle cycle. The 
synaptic vesicle cycle involves three phases : i) formation of synaptic vesicles and 
their organization into functional pools, during which neurotransmitter is loaded 
onto synaptic vesicles through neurotransmitter transporters ii) exocytosis, a 
process that involves docking of vesicles to the presynaptic plasma membrane and 
the docked vesicles undergo maturation, called priming. The primed vesicles fuse 
with the plasma membrane following the influx of calcium through voltage-gated 
calcium channels mediated by a calcium sensor iii) endocytosis or recycling of 
synaptic vesicles occurs following fusion, vesicles and vesicle associated proteins are 
recycled to sustain neurotransmitter release. 
The synaptic vesicle serves as an organelle for neurotransmitter storage and 
release. To do this, synaptic vesicles rely on restricted set of membrane proteins 
(Fig 1.1). The synaptic vesicle biogenesis involves a series of events starting from 
synthesis of proteins in the cell body, followed by their sorting and their targeting to 
the membrane along the axon. The formation of vesicles through endocytosis and 
the formed vesicles undergo a maturation process that includes the active uptake of 
neurotransmitter from the cytoplasm (Bennett and Scheller, 1994).  
Functionally, synaptic vesicles are distinguished into three types of pools basing on 
their differential ability to be recruited for fusion. The three pools are:  
 Readily Releasable Pool (RRP) 
 Recycling Pool 








Fig. 1.1. Model of synaptic vesicle. 3-dimensional pictorial representation of synaptic vesicle 
representing various proteins. Fig adapted from Takamori et al., 2006. 
According to Ting and Philips 2008, the RRP constitutes about 1-2%, the recycling 
pool 10-20% and the reserve pool of 80-90% when vesicle pools are expressed as 
percentages of the total synaptic vesicle cluster. RRP is the pool of vesicles that are 
available immediately on stimulation, and can be defined as those that are docked 
and primed at the active zone, rendering them fusion competent to be able to fuse 
upon arrival of an action potential (Schikorski et al., 2001, Rizzoli and Betz 2005). 
The second type of pool is the recycling pool, as the name implies, these vesicles 
are recycled repeatedly upon physiological stimulation. The recycling pool and 
readily releasable pool of vesicles are rapidly retrieved by endocytosis upon fusion 
with the presynaptic plasma membrane. Reserve pool is the third and the largest 
among the pools that do not contribute to neurotransmitter release. 
Exocytosis is a tightly regulated process that involves multiple intermediate steps in 
the release of neurotransmitter from synaptic vesicles present in the presynaptic 






regulate various intermediate steps of the synaptic vesicle release machinery 
(SNAREs, Munc18s, SNARE proteins, SNAP25, Syntaxin, Synaptotagmin, 
Complexins, RIMs, and Munc13s). Exocytosis involves three intermediate steps-
docking, priming and fusion. 
Synaptic vesicles from the reserve pool are docked to the release sites of the 
presynaptic membrane in a process known as docking. Docking of synaptic vesicles 
at the active zone is mediated by Munc18-1, a member of SM family of proteins and 
Rab family of proteins (Voets et al., 2001a; Weimer et al., 2003). The latter have 
also been found to play a role in priming. Munc18-1 interacts with Syntaxin1 in its 
closed confirmation and disrupts the formation of a functional SNARE complex, 
important for vesicle fusion (Dulubova et al., 1999). Formation of a functional 
SNARE complex is mediated by the activation of syntaxin1 by Munc13 that disrupts 
the Munc18-1 and syntaxin1 interaction. Therefore, allowing Munc13 family of 
proteins to be essential priming components of the release machinery (Basu et al., 
2005, Ma et al., 2011; Südhof 2012). Rab proteins are small GTPases that serve 
divergent functions from vesicular trafficking to the release of neurotransmitter. Rab 
proteins are involved in docking and priming through their interaction with RIM 
proteins (Rab3-interacting molecules). Members of the Rab protein family, Rab3 
(Wang et al., 1997) and Rab27 (Fukuda et al., 2003) bind to a heterodimer of RIM 
and Munc13 (Dulubova et al., 2005) promoting an indirect role for Rab proteins in 
synaptic vesicle docking and priming (Südhof, 2012).  
Docked vesicles are not yet fusion competent, hence they undergo a series of 
priming steps in order to be able to fuse rapidly in response to calcium influx. 
Several proteins are implicated to play a role in the priming process. Munc13, a 
mammalian homologue of Unc13 is an essential vesicle priming protein of active 
zones (Brose et al., 1995; Augustine et al., 1999). Fusion of a synaptic vesicle with 
its target membrane, following Ca2+ influx to release neurotransmitter into the 
synaptic cleft is a fundamental process essential to synaptic transmission. Many 
proteins are found to be involved in Ca2+-triggered exocytosis of synaptic vesicles. 






attachment protein receptors (SNAREs), Synaptotagmin1 and Complexin have been 
found to be the core components of the release machinery.  
 
SNARE proteins  are the central components of membrane fusion machinery that 
share a 60 amino acid coiled-coil domain called SNARE motif (Weimbs et al., 1997) 
and SNARE proteins form extremely stable complexes when bound to each other 
through their SNARE-motifs. SNAREs can be classified into two types basing on their 
localization: v-SNAREs associated with vesicles and t-SNAREs, localized on the 
target membrane (Rothman 1994). 
 
One of the critical steps of exocytosis is mediated by a SNARE complex, formed by 
two t-SNAREs-Synataxin1a and SNAP-25 (N-ethylmaleimide sensitive factor 
attachment protein-25), and a v-SNARE-Synaptobrevin/VAMP2 (Sutton et al., 
1998). These three proteins of SNARE complex form a parallel four-helix bundle 
aligning vesicle and plasma membrane in a zippering fashion (Hanson et al., 1997). 
Munc13 promotes SNARE complex assembly by disrupting the interaction of the 
Munc18-Synataxin complex that is known to inhibit SNARE complex formation. In 
addition to SNARE proteins, Ca2+-triggered neurotransmitter release is mediated by 
Synaptotagmin1, a Ca2+ sensor protein present on synaptic vesicles (Brose et al., 
1992). It is believed that calcium bound to the C2-domains of Synaptotagmin1 
mediate buckling of the active zone membrane with SNARE complex. This brings 
membranes together in a zippering fashion allowing the completion of the fusion 
process (Martens et al., 2007; Ting and Phillips, 2008). 
 
Vesicle fusion and neurotransmitter release at the plasma membrane occurs by two 
modes. Neurotransmitter release from synaptic vesicles occurs either through 
complete fusion releasing all of its components into the synaptic cleft in a process 
known as full-fusion or full-collapse model. The other way in which the 
neurotransmitter release is via a small opening of a fusion pore in a process known 
as Kiss-and-run mode of fusion or flicker-fusion. The unaltered synaptic vesicles 






run fusion influences neurotransmitter release at CNS synapses is still under debate 
and is the topic of research yet to be resolved (Smith et al., 2008). 
 
Endocytosis is an essential mechanism for the retrieval of synaptic vesicles to 
sustain synaptic transmission by refilling the vesicle pool and facilitating continuous 
release. During intense synaptic activity, vesicle release can reach maximum 
leading to the depletion of vesicles; hence vesicles are retrieved and recycled via 
endocytosis to maintain the process of neurotransmission. Depending on the 
synapse in the brain, the process of vesicle retrieval and recycling can occur by 
three modes i) Clathrin-mediated endocytosis ii) kiss-and-run, and iii) activity-
dependent bulk endocytosis (ADBE) (Nyugen et al., 2014). Depending on the 
synaptic activity, different synapses in the brain adopt a different mode of retrieval. 
For example, kiss-and-run mode of endocytosis varies between small and large 
nerve terminals with an estimation of 80% in small nerve terminals like 
hippocampal boutons and around 3% at the Calyx of Held, although controversies 
still remain (Smith et al., 2008).  
1.4. Active zone 
Neurotransmitter release occurs at highly specialized area on the presynaptic 
plasma membrane called the active zone (AZ). The term active zone was first used 
by Couteaux and Pecot-Dechavassine in 1970.The regulated neurotransmitter 
release at the active zone involves a series of membrane trafficking events and the 
synaptic vesicle cycle. Each AZ is defined by the presence of an electron dense 
membrane specialization comprised of a meshwork of proteins called the cytomatrix 







Fig.1.2. Synaptic vesicle protein machinery implicated in the 
neurotransmitter release process. Fig adapted from Mittelstaedt et al., 2010. 
Five major multi-domain proteins-RIMs, Munc13s, CAST/ELKS proteins, 
Piccolo/Aczonin and Bassoon have been found at the CAZ. Bassoon and 
Piccolo/Aczonin are two large protein families that have been identified as 
vertebrate specific whereas the RIMs, Munc13s and CAST/ELKS proteins are found 
to be evolutionarily conserved (Gundelfinger and Fejtova 2012). The CAZ proteins 
form a supramolecular complex and regulate key steps of neurotransmitter release 
such as organization of synaptic vesicles into distinct pools (Rizzoli and Betz 2005), 
docking and priming of synaptic vesicles, recruitment of calcium channels to the 
release sites and tethering of vesicles and calcium channels to cell-adhesion 
molecules. (Südhof 2012) 
RIMs or Rab3 interacting molecules are a family of multi-domain proteins (Wang et 
al., 1997 and Schoch et al., 2010) and the central elements of CAZ. RIMs mediate 
presynaptic functions and plasticity through their interaction with all other active 
zone proteins and presynaptic components (Wang et al., 2009;Schoch et al., 
2010).RIM proteins are involved in two principal functions :i) docking and priming of 
synaptic vesicles and ii) recruitment and tethering of Ca2+ channels to the active 
zone. RIM binds to a homodimer of Munc13 thus promoting synaptic vesicle priming 






impairment of synaptic vesicle priming (Andrews-Zwilling et al., 2006). This 
impairment was rescued by the expression of monomeric Munc13 (Deng et al., 
2011). 
Earlier, an indirect interaction of RIM proteins to calcium channels was observed by 
binding to RIM-binding proteins  (RIM-BPs) (Wang et al., 2000) that in turn bind to 
L-,N-, P/Q-type Ca2+ channels (Hibino et al., 2002). Later, a direct interaction of 
RIM with N- and P/Q-type Ca2+channels was identified that is essential for recruiting 
ca2+ channels to active zones. Conditional knock-out mice lacking all RIM isoforms 
containing a PDZ domain exhibit a selective loss of Ca2+ channels at the active 
zones and are rescued by a RIM fragment with PDZ domain. (Kaesar et al., 2011). 
Munc13-, a mammalian homologue of Unc13 is an essential vesicle priming protein 
of active zones (Brose et al., 1995; Augustin et al., 1999). Munc13 proteins 
promote synaptic vesicle priming by activating syntaxin1, a member of the SNARE 
complex essential for fusion (Ma et al., 2011, Südhof, 2012). Munc13-1 binds to 
Ca2+-Calmodulin and mediates presynaptic short-term plasticity (Junge et al., 2004; 
Lipstein et al., 2013).Munc13 modulates neurotransmitter release by forming an 
interaction web with the active zone components Piccolo, Bassoon, CASTs and RIMs 
(Wang et al., 2009). Recent electron tomography studies on hippocampal 
organotypic cultures indicate that Munc13s not only participate in the priming 
process but also aid in the recruitment of synaptic vesicles and docking along with 
CAPS proteins and neuronal SNARES with the exception of Synaptotagmin or 
Complexin (Imig et al., 2014) . 
Bassoon (tom Dieck et al., 1998) and Piccolo (Cases-Langhoff et al., 1996 are the 
two largest vertebrate specific proteins of the CAZ that are highly homologous and 
share ten so-called Piccolo-Bassoon homology domains (PBH). Most of the studies 
involving Piccolo deficient synapses do not show any major impairment in synaptic 
transmission, in contrast synapses lacking Bassoon or both Piccolo and Bassoon 
involve in regulating several stages of synaptic transmission. Moreover, they exhibit 
different functions at different synapses from small hippocampal synapses to large 






(Piccolo), most of the studies were done using partial knock-out or knock-down 
strategies using RNA interference. 
In addition to Piccolo-Bassoon homology domains, Piccolo consists of two C2 
domains (different from others) and one of the C2 domain binds to Ca2+, suggesting 
an indirect role for Piccolo in the process of Ca2+-mediated  exocytosis which is yet 
to be resolved (Gerber et al., 2001, Südhof, 2012). Hair cell ribbon synapses lacking 
Bassoon show a reduction in the number of calcium channels, reduced 
neurotransmitter release and an impairment in vesicle replenishment thus 
suggesting a role of Bassoon in organizing Ca2+ channels and vesicles to release 
sites at ribbons and promoting vesicle replenishment (Frank et al., 2010).Disruption 
of Bassoon at end bulbs of Held synapses resulted in a reduction of the readily 
releasable pool size and in the rate of vesicle replenishment. In addition, increase in 
vesicular release probability and postsynaptic densities suggesting a role of Bassoon 
in homoeostatic plasticity and promoting vesicle replenishment (Mendoza et al., 
2013). Piccolo and Bassoon have various functions like maintaining synaptic vesicle 
clustering and synapse integrity via ubiquitination (Waites et al., 2013; Mukherjee 
et al., 2010). 
Bassoon and Piccolo are vertebrate-specific proteins that are possibly adding 
vertebrate-specific features to the presynaptic nerve terminals. Exogenous 
expression of full-length and deletion constructs of Bassoon did retain their 
presynaptic targeting capacity in cultured hippocampal neurons (Dresbach et al., 
2003). The C-terminal region of Bassoon with a stretch of glutamine residues also 
showed presynaptic targeting in cultured hippocampal neurons. This led to the idea 
that the presynaptic targeting of C-terminal region of Bassoon (aa3263-3938) could 
be due to its binding to other yet unknown proteins. In the process of identifying 
interacting partners of Bassoon, Mover, a novel also vertebrate specific protein, was 
identified in yeast 2-hybrid assay using the C-terminal region of Bassoon as bait 







1.5. Presynaptic targeting of proteins 
 
Little is known about the targeting of proteins to the presynaptic membrane. The 
proteins synthesized in the cell body are targeted to various components of synaptic 
vesicles and participate in various phases of the synaptic vesicle cycle either alone 
or by interacting with other proteins. The proteins associated with the synaptic 
vesicle cycle are recycled during endocytosis suggesting the need for sorting 
mechanisms that generate highly organized synaptic structures at the presynaptic 
plasma membrane. Each protein of the synaptic vesicle may undergo selective 
sorting consisting of several signals - mediating its targeting to the TGN, the plasma 
membrane and endosomes. Having several signals mediating the targeting of these 
proteins, makes understanding the mechanisms underlying their sorting more 
complicated and difficult to characterize. Furthermore, no common targeting 
information, sequence or motif is known to be involved in the sorting of proteins. 
Moreover, the targeting signals involved in polarized trafficking of SV proteins are 
more complicated to understand. The targeting of proteins to synaptic vesicles 
along the axon may rely on protein-protein, protein-lipid interactions and post-
translational modifications  
(Bonanomi et al., 2006). 
1.6. Modulation of neurotransmitter release 
Synaptic plasticity, the central and key element of information processing between 
neurons in the brain is characterized by the activity-dependent changes in strength 
of synaptic connections that can be long-term or short-term. Synaptic plasticity can 
be divided into pre- and post-synaptic plasticity. Considerable progress has been 
made in elucidating the mechanisms of post-synaptic plasticity. The complex 
synaptic vesicle release machinery at the presynaptic terminal makes it difficult to 
understand the molecular and cellular mechanisms underlying presynaptic plasticity.  
One possible approach to studying presynaptic plasticity is to determine the 
mechanisms in neurotransmitter release. Neurotransmitter release is modulated 






exocytosis. The latter, in turn is modulated through second second-messenger 
mediated signaling pathways resulting in phosphorylation of proteins by protein 
kinases, involved in the exocytotic release machinery (Leenders and Sheng, 2005). 
Protein phosphorylation plays an important role both in pre-and post-synaptic 
plasticity. Several proteins that are involved in multiple steps of synaptic vesicle 
cycle are also regulated by phosphorylation and the best studied and characterized 
example is Synapsin. Phosphorylation of Synapsin results in its dissociation from 
SVs in the reserve pool and mobilizing SVs to the active zone for exocytosis (Hosaka 
et al., 1999). Phosphorylation of proteins is mediated by different protein kinases 
such as ca2+-Calmodulin dependent protein kinase II (CaMKII), protein kinase A 
(PKA) and protein kinase C (PKC). 
Ca2+-triggered neurotransmitter release occurs via exocytosis of synaptic vesicles 
with an influx of Ca2+, upon arrival of an action potential. The  
 
Fig 1.3. Phosphorylation of proteins implicated in exocytosis. Phosphorylation of 
synaptic vesicle proteins, proteins of the SNARE complex, calcium channels by CaMKII or PKC or PKA alone or in 






release of neurotransmitter from vesicles occurs with a certain probability known as 
release probability. The release probability can be defined as the probability with 
which a number of vesicles are released immediately in response to an action 
potential (Leenders and Sheng, 2005). The release probability depends on several 
factors such as the size of the readily releasable pool,Ca2+-sensitivity of release, 
vesicular release  and the responsiveness of the release machinery to 
Ca2+influx(Subramanian, 2011). 
1.7. Ca2+ and Calmodulin in the brain 
 
Calcium ions play essential roles in many cellular processes including transcription 
control, neurotransmitter release, muscle contraction and cell survival. Calcium ions 
form a gradient across the membrane being at higher concentrations extracellular 
and with low intracellular concentrations. Many proteins are involved in Ca2+-
mediated signaling process altering their activity in response to the availability of 
free Ca2+, but the interaction of proteins with Ca2+ is indirect and modulated by 
Ca2+-binding proteins. One such protein is Calmodulin (CaM), highly conserved and 
best studied among the E-F hand family of Ca2+- sensing proteins that has been 
implicated to participate in many cellular functions. 
 
Calmodulin (CaM) is an E-F hand family member of Ca2+- sensing proteins that 
comprises of four E–F hands. Calmodulin consists of an N-terminal globular domain 
connected by a short linker to a C-terminal domain. Both N- and C-terminal 
domains each, have a pair of E-F hands accommodating four Ca2+ ions. The two 
domains of CaM adopt different conformations in the presence or absence of Ca2+. 
The N-terminal domain of apo-CaM adopts a closed conformation in the absence of 
Ca2+while the C-terminal adopts a semi-open conformation exposing hydrophobic 
methionine residues to interact with target proteins. Binding of Ca2+ changes both 
domains of CaM to produce an open conformation leading to structural 
rearrangements exposing hydrophobic residues accessible to target proteins (Chin 
and Means, 2000).The target proteins can be divided into two groups of calcium-







Most of the Ca2+-dependent CaM interacting proteins - are neuronal   proteins. 
Nevertheless the Ca2+sensor essential for neurotransmitter release is 
Synaptotagmin (Brose et al., 1992). However, Calmodulin- aids in regulating the 
recruitment of synaptic vesicles through the activation of Ca2+- Calmodulin 
dependent protein kinases (CaMKs), ultimately leading to the phosphorylation of 
vesicle proteins. Phosphorylation of proteins is an important process that modulates 
presynaptic changes and plasticity.  
1.8. Aims of this study 
Mover is a novel vertebrate-specific protein of 266 amino acids (apparent molecular 
weight 30KDa) (Kremer et al., 2007. Mover has also been identified in SV proteomic 
analysis as SVAP-30 (synaptic vesicle associated protein-30) (Burre et al., 2006; 
Böyken et al., 2013) Evident from subcellular fractionation experiments showing the 
association of Mover with synaptic vesicles (Kremer et al., 2007; Ahmed et al., 
2013). The Mover gene shares 49% amino acid homology with the Tprg gene that is 
expressed in skin and also is hence also known asTprgl1 (Tprglike-1) (Antonini et 
al., 2008). 
Over expressed recombinant Mover in neuronal and non-neuronal cells, forms 
aggregates due to its partial solubility. There are no predicted homology domains to 
study except for a predicted HSac2domain (aa53-163) and a Calmodulin binding 
site (aa206-218) identified through database analysis. However, the C-terminus of 
Mover is highly conserved in all vertebrates, while its N-terminus is less well 
conserved. Mass spectrometry studies of presynaptic proteins detected a threonine 
phosphorylation site at amino acid 13 (Munton et al., 2007). Data base analysis 
suggests additional predicted phosphorylation sites at aa14 (Serine), aa64 
(Threonine), aa 257 (Tyrosine) and aa221 (Serine). 
Mover is a presynaptic protein that exhibits differential expression among synapses 
in the brain, raising the possibility that Mover may account for the presynaptic 
functional heterogeneity (Kremer et al., 2007). This is also evident from the 
differential expression of Mover at a subset of end bulbs of Held, in the auditory 






In order to understand the role and function of Mover, it is essential to identify the 
functional domains of Mover. The aims of the current study were to: 1) generate a 
Mover Knock-out mouse line and 2) characterize the functional domains of Mover 
and their role in  
1) Subcellular localization 
2) Dimerization/Oligomerization 
3) Binding interactions with Munc13, Calmodulin and Bassoon 
4) Synaptic vesicle recycling. 




2. Materials and Methods  
 
2.1. Materials 
2.1.2. Chemicals for biochemistry 
Reagents Company Catalogue number 
Calmodulin Human Enzo BML-SE325-0001 
CaMKII Enzo BML-SE470 
CaMKII England Biolabs P6060L 
Gelcode Blue protein stain Thermo Scientific 24594 
Cheluminate HRP femto 






Glutathione Sepharose  GE HealthCare 17-5132-01 
Protein A/G agarose Pierce PI-20423 
L-Gluthione Reduced Sigma G4251-109 
Nonidet P-40  Applichem A1694,0250 
Thrombin Sigma T6884-100UN 
Lysozyme from Chicken Sigma 62970-1G-F 
Protease Inhibitor cocktail 
tablets EDTA-free 
Roche 04693132001 
MES SDS Running buffer  Life Technologies NP0002 
MOPS SDS Running buffer Life Technologies NP0001 
Gel Blot Paper   Omni Lab   GB003 
Ficoll Applichem A2252,0100 
Novex 4-12% Bis-Tris Gels Life Technologies NP0335BOX 












10X Laemli buffer 
Tris    29g 
Glycine   144g 
SDS    10g 
 
Western Blot Buffer 
Dis.H2O   760ml 
Methanol   200ml 
25X Transfer Buffer 40ml 
Make the day before 
 
1X TBST 
Tris HCl   0.02M 
NaCl    0.137M 
Tween 20   0.1% 
 
Blocking reagent 4% 
4 gm of milk powder in 100ml of TBST 
Concentration can vary from 1% to 5%. 
Instead of milk powder 10% FCS can also be used. 
 
Sample Buffer 
10% SDS   20ml 
DTT    1.542g 
1M Tris (PH: 6.8)  6ml 
Glycerin   10ml 
Bromophenol Blue 5mg 
Make it to 50ml. 
 
 
Transfer Buffer 25X/500ml 
Tris    18.2g 














Chemical Company Catalogue no 
Tetrodotoxin Tocris Bioscience 1069 
4-AP     Sigma 275875-1G 
Forskolin    Sigma F6886 
MG-132    Sigma M7449-200UL 
 




Neurobasal Medium  
    
Invitrogen,  21103-049 
Hanks buffered salt 
solution    
Invitrogen,  14170-088 
Fetal Calf Serum (FCS)        
OPTIMEM  Invitrogen,  31985-047 
Trypsin-EDTA 0.05%    PEI  Invitrogen 25300 
Trypsin 2.5% Invitrogen 15090-046 
Pen strep  15140-122 
B27 supplement     17504-044 
L-Glutamine 200mM  25030-024 
PEI  Sigma 482595 
poly L-lysine Sigma P4832 
Lipofectamine 2000 Invitrogen  
PEI for transfection Sigma  
1X Dulbecco's PBS Invitrogen 14190-094 





2.1.6. Reagents for molecular biology 
 
Reagent Company Catalogue no 
CIP     England Biolabs M02905 
Restriction endonucleases 
  
England Biolabs ----------------- 
Gene ruler 1Kb DNA 




Gene ruler 100bp DNA 









DreamTaq Green PCR 








Kit Company Catalogue no 
Plasmid Endo-free Maxi Kit Qiagen 12362 
PCR and Gel Purification 
Kit 
Promega A9281 
BCA assay kit Thermo scientific 23227 
Spectra Por Dialysis 
membranes 
Omni Lab 132650 
Spin-X-UF  Protein 
Concentrator 
Corning 431487 






2.1.8. Cell lines and bacterial strains 
 
Eukaryotic cell lines 
HEK 293T:  Human embryonic kidney tumor cell line, additionally    
          expressing  "SV40 large T-Antigen", capable for DNA-   
          replication of episomal plasmids 
 
E.coli XL1 Blue 
Rosetta Electro competent cells 
2.1.9. List of primary antibodies 
 
Antibody Company  Western ICC 
Rb Mover Synaptic Systems 248003 1:2000 1:1000 
Rb Synapsin 1/2 Synaptic Systems 106002  1:2000 
Ms MAP2 Synaptic Systems 188011   
Gp MAP2 Synaptic Systems   1:1000 
Ch MAP2 Biosensis C-1382-50  1:6000 
Ms Synaptophysin Sigma S5768 1:2000 1:1500 
Rb GFP Synaptic Systems 132002 1:2000 1:1000 
Equipment Company 
SDS-PAGE Bio-Rad 
Glass-Teflon potter     Omni Lab 
Sterile hood for cell culture work  Thermo Electron 
  Zeiss 
Metamorph analysis software   Visitron Systems, 
Inverted Fluorescence Microscope   
Centrifuges      Eppendorf 
Ultracentrifuges     Beckman Coulter,  





Ms Bassoon Enzo SAP7F407  1:1000 
Ms Myc Calbiochem OP10   
Ms GFP Thermoscientific MA5-15256   
Ch GFP Abcam 13970  1:2000 
Rb β-3-tubulin Synaptic Systems 302302 1:2500  
Rb VAMP2 Synaptic Systems 104202  1:1000 
Gp VGLUT1 Synaptic Systems 131004  1:1000 
Gp VGAT Synaptic Systems 135304  1:1000 
Ms GFAP Synaptic Systems 173011  1:1000 
Ms Calmodulin Merck Millipore 05-173  1:2000 
Ms CaMKII Abcam 22609  1:1000 
CaMKII-P Merck Millipore 101004  1:1000 
Gp Synaptophysin Synaptic Systems 101004  1:1000 
Ms Synaptotagmin Synaptic Systems 105311  1:100 
 
2.1.10. Secondary antibodies 
 
Immunofluorescence 
Secondary antibodies coupled to alexa flour 488, Cy3 and 647 at a concentration of 
1:1000 were used to stain neurons and HEK cells appropriately and as required. 
Western blots 
Anti-Mouse and anti-Rabbit Horse-radish peroxidase at a concentration of 1:10000 












2.1.11. List of Plasmid DNA's 
 
pEGFPC-1 available in the lab 
 
pEGFPC-1-Helix Long (53-266) cloned personally 
 
pEGFPC-1-Helix Short (53-253) Genscript 
 
pEGFPC-1-HSac cloned personally 
 
pEGFPC-1-DE2 cloned personally 
 
FL-Mover- pEGFPN-1 cloned personally 
 
52-266- pEGFPN-1 cloned personally 
 
91-266-pEGFPN-1 cloned personally 
 
52-253- pEGFPN-1 Genscript 
 
53-163- pEGFPN-1 Genscript 
 
ΔExon2 (93-151)- pEGFPN-1 Genscript 
 
pEGFPC-1-90 available in the lab 
 
pEGFPC-1-180 available in the lab 
 
pEGFPC-91-180 available in the lab 
 
pEGFPC-181-266 available in the lab 
 
pEGFPC-91-266 available in the lab 
 
T13D- pEGFPN-1 Genscript 
 
T13A- pEGFPN-1 Genscript 
 
T13A-T64A- pEGFPN-1 Genscript 
 
T13A-Y257F- pEGFPN-1 Genscript 
 
T64A- pEGFPN-1 Genscript 
 








Mover-myc available in the lab 
 
GFP-Mover (Ku) available in the lab 
 
GFP-Mover available in the lab 
 
GFP-VAMP available in the lab 
 
Synaptophysin mOrange Available in the lab 
 
Synaptophysin-mOrange-pHluorin Provided by Dr. Camin Dean 
 
EGFP-Munc-13 available in the lab 
 
Complexin-1, 2, 3 and 4   
   
provided by Dr. Kerstin Reim  
     
F206R-mGFP    
  






GST-Calmodulin available in the lab 
 
GST-Mover     
   
available in the lab 
GST      
  
available in the lab 
GST-F206R     
  
Genscript 















2.2. Experimental methods 
2.2.1. Neuronal cultures 
 
Coverslips- 
Cover slips were sterilized by autoclaving at 180°C for 2 hours. These cover slips 
were distributed into 24-well plate, rinsed once with 1X DPBS and coated with PEI 
(rat cultures) and PLL (mouse cultures) for 2 hours at 37°C in the incubator. PEI 
was removed by three washes with 1X DPBS and stored in the incubator. 
Preparation of primary hippocampal cultures  
1x Dulbecco’s PBS (Gibco) 
1x Hank’s Buffered Salt Solution (Gibco) 
1x trypsin solution (Sigma) 
 
Plating Medium: 
1x Dulbecoo’s Modified Eagle Medium (DMEM), Invitrogen 
10% (v/v) Fetal Calf Serum (FCS) 
1% (v/v) Penicillin/Streptomycin 
2 mM Glutamine 
 
Growth Medium: 
1x Neurobasal Medium, 
B27 supplement 
0.5 mM Glutamine 
1% (v/v) Penicilline/Streptomycin 
Hippocampi were dissected from E19 rat embryonic brains and trypsinized for 20 
mins at 37°C with 0.25% trypsin. After trypsinization, the hippocampi were washed 
three times with HBSS and triturated through 20G and 25G needles for three times 
each, in order to dissociate the neurons. The dissociated neuronal suspension was 
then passed through the filter to remove the residual tissue. The cells were counted 





The cell suspension and trypan blue were mixed at 1:1 ratio and the resultant 
mixture was put on the Haemocytometer to count the cells. Viable cells do not take 
up dye and appear as white spots. The cells were diluted with plating medium to 
have a low-density culture of 50.000 cells/well and plated on to the PEI coated 
cover slips in a 24-well plate. All the cells were maintained at 37°C with 5% CO2. 
The plating medium was replaced with growth medium the following day. 
Primary cortical neurons  
Cortices from the hippocampal preparation of E19 embryos were collected and 
chopped into small pieces with a scissor after removing meninges. The same 
protocol is followed as described above for hippocampal cultures. The dissociated 
cells were plated at 1 million cells per well of a 6-well plate coated with PEI. Drug 
treatment experiments were done using 1 million cells per well of a 6/well plate. 
Mover knock-out mouse hippocampal cultures 
P0 litter from heterozygous Mover mice were used for cultures after genotyping. The 
same protocol is followed for both hippocampal and cortical mouse neuronal 
cultures as described for rat embryonic cultures. Mouse hippocampal neurons were 




Calcium phosphate transfection 
Primary cultured hippocampal neurons were transfected using calcium phosphate 
transfection method (for long-term expression) on 3DIV. First the DNA-CaCl2 
mixture was made accordingly: 
DNA-CaCl2 mixture for 3 Coverslips 
DNA-3µg 
CaCl2-5.6µl 






Then add 45µl of transfection buffer slowly and drop wise with gentle mixing. Store 
the mixture for 20-30 mins at RT. During this incubation, the medium on the 
neurons was exchanged with pre-warmed Opti-MEM and placed back into the 
incubator at 37°C and 5% CO2. Removed growth medium is stored in a petri-dish 
and placed into the incubator for later use. Add 30µl of the transfection mixture per 
well of a 24-well plate and the neurons were placed back into the incubator for 75 
mins. Neurons were washed by exchanging the medium with 1ml of pre-warmed 
neurobasal once, followed by 750µl twice. Finally the medium was exchanged with 
stored growth medium.  
 
Lipofectamine transfection 
Primary cultured hippocampal neurons were transfected using lipofectamine 
transfection method (for short-term expression). Firstly Opti-MEM and growth 
medium were pre-warmed at37°C in the water bath. 
DNA-lipofectamine mixture for 3 coverslips 
Epi 1. 75µl of pre-warmed Opti-MEM+3µl of lipofectamine reagent were added and 
mixed well 
Epi 2. 75µl of pre-warmed Opti-MEM + 3µg of DNA were added and mixed well 
Mix both 1 and 2 and incubate for 30 mins at RT. 
 
The cultured medium from the neurons is exchanged with pre-warmed growth 
medium. The cultured medium is stored in a petri-dish and placed it in incubator for 
later use. Add 50µl of the transfection mixture per well of a 24-well plate and the 
neurons were placed back into the incubator for 75 mins. Neurons were washed by 
exchanging the medium with 1ml of pre-warmed neurobasal once, followed by 










Primary antibody buffer    Secondary antibody buffer 
10% 10X PBS     10% 10X PBS 
10% FCS      -------- 
5% Sucrose      5% Sucrose 
2% BSA      2% BSA 
0.3% Triton X-100     0.3% Triton X-100 
 
Mounting medium 




Mix by vortexing. 6 ml of H2O was added and mixed well, incubated for 2 hrs at RT. 
12ml of 0.2M Tris pH 8.5 was added and heated at 50°C for 10 mins. Centrifuge at 
5000g for 15 mins. A final concentration of 2.5% DABCO was added, aliquot and 
stored at -20°C. 
 
Eukaryotic cells and primary hippocampal neurons (14DIV or 7DIV) are fixed with 
4% PFA in PBS for 20mins at RT. Cells were washed three times with 1X PBS for 5 
mins each. Cells were permeabilized and blocked for 30 mins-1 hour using primary 
antibody buffer. After blocking, respective antibodies diluted in primary antibody 
buffer were added and incubated overnight at 4°C. Following day, the cells were 
washed three times of 10 mins each with 1X PBS and incubated with secondary 
antibodies coupled to Alexa 488, Alexa Cy3 or Alexa 647 diluted at 1:1000 in 
secondary antibody buffer for 30mins-1 hour at RT in the dark. Further washes were 
done with 1X PBS for three times of 10 mins each and the cover slips were mounted 
using mounting medium containing Mowiol. Mounted cover slips were air-dried in 







2.2.1.4. Synaptotagmin 1 antibody uptake assay 
 





200mM HEPES pH 7.4 
300mM Glucose 
 
Synaptotagmin 1 is an integral membrane protein of synaptic vesicles that serves as 
a calcium sensor in the process of vesicular trafficking and exocytosis, thus linking 
calcium influx during depolarization to neurotransmitter release. Upon Ca2+ binding, 
Synaptotagmin triggers exocytosis of synaptic vesicles. Antibodies raised against 
luminal domain of Synaptotagmin are used to label recycling synaptic vesicles in live 
cultured neurons. Cultured rat hippocampal neurons were co-transfected on 3DIV 
with either with mGFP, Mover-mGFP or 52-266-mGFP along with Synaptophysin 
mOrange. Following expression, Synaptotagmin antibody uptake was performed on 
14DIV by adding 200µl of the depolarization buffer containing Synaptotagmin 
antibody at a dilution of 1:100, incubated at RT for 90secs. Neurons were washed 
with pre-warmed neurobasal medium for two times and third time for 5 mins in the 
incubator. Following the third was in the incubator for 5 mins; neurons were fixed 
with 4% PFA, stained with anti GFP and incubated overnight at 4°C. Following day, 
the cells were washed with 1X PBS for three times of 10 mins each. Secondary 
antibodies coupled to alexa flour 488 against rabbit GFP and alexa 647 for mouse 
Synaptotagmin.  
 
2.2.1.5. Drug treatment and protein extraction 
 
Hypotonic buffer  








Homogenization buffer  
320mM sucrose 
1mM EDTA  
10mM Tris-HCl  
pH 7.4 
 
Fourteen DIV and twenty one DIV hippocampal neurons growing in 6-well plates at 
a density of 100,000cells/well were treated with 50 μm forskolin for 8 h, 50 μm 
MG132 for 8 h, 1 μm TTX for 48 h, 4-AP-50µM for 30 h or in control conditions. 
Neurons were washed twice with PBS and 1 ml of hypotonic buffer was added per 
well for 5 min. Cells were harvested in 0.5 ml of homogenization buffer by scraping 
and passed through a 25-gauge needle 10 times. A final concentration of 150 mm 
NaCl was added to the lysate. Cell lysates were centrifuged at 4000 rpm for 10 min 
to pellet nuclei and cellular debris. The supernatant was collected and the protein 
concentration determined by Nano Drop. 100 micrograms of total protein per lane 
was resolved by SDS-PAGE and analyzed by immunoblotting for Mover (30 kDa 
band) and β-3-tubulin as a control (55kDa band).  
2.2.2. Maintenance of HEK293T cell lines  
 
1x Dulbecco’s PBS (Gibco) 
1x trypsin-EDTA solution (Sigma) 
 
Growth Medium: 
1x Dulbecoo’s Modified Eagle Medium (DMEM), Invitrogen 
10% (v/v) Fetal Calf Serum (FCS) 
1% (v/v) Penicillin/Streptomycin 
 
HEK293T cells were grown in T100 flasks at 37°C with 5% CO2. Cells were washed 
once with 1X DPBS and trypsinized with 2ml of 1X trypsin-EDTA solution for 1-2 
mins on the bench in the sterile hood. Detached cells were collected by adding 10 





was resuspended by adding 10ml of pre-warmed growth medium to have a single 
cell suspension. 
Freezing and thawing of HEK293T cells 
Freezing Medium 
1x Dulbecoo’s Modified Eagle Medium (DMEM), Invitrogen with  
20% FBS and  
10% DMSO 
 
HEK293T cells were grown in T75 flasks at 37°C with 5% CO2. Cells were 
trypsinized as described and cell pellet was resuspended in 500µl of growth 
medium. Resuspended cell suspension and the freezing medium were added at 1:1 
ratio, transferred into 2ml cryovials and transferred incubated at -80 °C overnight in 
isopropanol-surrounded plastic tanks to assure a slow decrease in temperature. The 
following day, cryovials were transferred into a liquid nitrogen tank for long-term 
storage.  
 
Thawing of HEK293T Cells 
 
Cells frozen in liquid nitrogen were quickly thawed at 37 °C in a water bath. Cells 
were then transferred into a 15ml falcon tube with 10 ml fresh growth medium and 
sedimented at 1000rpm for 5mins to remover residual DMSO. Sedimented cells 
were then resuspended in 10ml of growth medium and plated onto the 10cm dishes 
or T75 flask as required. Cells were further maintained and cultured as described. 
 
Transfection of HEK293T cells 
HEK293T cells plated on 10cm cell culture dishes were used for transfected with PEI 
transfection method. 
Transfection mixture for one 10cm dish 
22.5µg of DNA 





make it to 1ml with pre-warmed OptiMEM medium 
Transfection mixture was mixed gently and incubated for 20-30 mins at RT.1ml of 
the transfection mixture was added to the dish and incubated at 37°C from 30 
mins-2hrs in the incubator. Cells were washed by exchanging the medium with 10 
ml of pre-warmed growth medium.  
 
2.2.3. Biochemistry 
2.2.3.1. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 
10X Running buffer/1 litre 
Tris    29g 
Glycine   144g 
SDS    10g 
 
Proteins were separated using SDS-polyacrylamide gel electrophoresis where in SDS 
is an anionic detergent that imparts a negative charge to the linearized proteins. 
The amount of SDS bound is proportional to the molecular weight of proteins and 
migrate towards anode. The smaller the percentage of acrylamide the larger the 
size of the proteins resolved. The different percentages of gels used to separate 
proteins are tabulated below. 
Resolving gel Stacking gel 
 8% 10% 12%  5% 
H2O 2.31ml 1.98ml 1.65ml H2O 3.4 ml 
Acrylamide 1.34 ml 1.67 ml 2 ml Acrylamide 850µl 
1.5M Tris 
pH 8.8 
1.27 ml 1.27 ml 1.27 ml 1.0M Tris 
pH 6.8 
625µl 
10% SDS 50µl 50µl 50µl 10% SDS 50 µl 
10% APS 34µl 34µl 34µl 10% APS 50 µl 







Proteins separated through polyacrylamide gel electrophoresis are transferred on to 
either PVDF or nitrocellulose membrane for detection through antibodies. 
Western blot transfer 
Transfer buffer 
Tris buffered saline 25X   40 ml 
Methanol      200 ml 
make it to 1 liter with water 
 
Tris buffered saline 25X 
 
Tris      18.2g 
Glycine     90g 
 
Semi-dry transfer was performed for all the experiments. For semi-dry transfer, the 
gel and activated PVDF membrane were sandwiched between two blotting pads on 
each side. Transfer was performed at 64mA for 1one hour at RT. 
Western blot detection 
1X TBST 
 
Tris HCl     0.02M 
NaCl      0.137M 
Tween 20     0.1% 
 
After transfer, membranes were blocked with 4% milk in TBS (for pre-cast Bis-Tris 
gels) or 10% FBS in TBS (for poured gels) for an hour at RT to avoid unspecific 
binding of antibodies. After blocking, the membranes were probed with respective 
antibodies diluted in blocking buffer overnight. Following day, the membranes were 
washed three times with 1X TBST for 10 mins each. The membrane is incubated 
with secondary antibody conjugated to Horse-radish peroxidase at a dilution of 
1:10000 in 1X TBST for 1 hour at RT (for poured gels) or 4% milk in 1X TBST at 
4°C for 1 hour (for pre-cast gels). The membrane was washed three times of 10 
mins each with 1X TBST at RT. For the detection of proteins, CheLuminate-HRP 





peroxide catalyzed by HRP. The membrane was incubated in CheLuminate-HRP 
Femto detects solution for 5 mins in the dark and exposed to hyper film ECL 
(BioZym) for the visualization of proteins. 
 
Stripping and reprobing the western blot 
Stripping buffer-100 ml 
SDS 10%     20ml 
Tris HCl pH 6.8, 0.5M  12.5ml 
Ultra-pure water    67.5ml 
Add 0.8 ml ß-mercaptoethanol under the fume hood. 
 
Add the buffer to a small plastic box which has a tight lid. Use a volume that would 
cover the membrane. Add the membrane and incubate at 50°C for up to 20 minutes 
with some agitation. Rinse the membrane under running water tap for 2-3 times. 
Traces of ß-mercaptoethanol will damage the antibodies. Wash extensively for 5 
minutes in TBST for twice and then go for blocking. 
 
2.2.3.2. Antibody characterization 
 
Several versions of Mover antibodies were present in the lab. To detect the best 
working antibodies, two approaches were used-one is western blotting and the 
other immunofluorescence, Cell lysates expressing GFP-Mover, Mover-mGFP and 
TPRG-mGFP were separated by SDS-PAGE and transferred onto PVDF membranes. 
The separated proteins were immunoblotted with the several versions of Mover 
antibodies. Using immunofluorescence, 14 DIV rat embryonic cortical and 
hippocampal neurons were fixed and stained with Mover antibodies to detect 
endogenous mover, and HEK293T cells over-expressing GFP-Mover, Mover-mGFP 
and TPRG-mGFP were fixed and stained with Mover antibodies to detect the 
specificity of Mover antibodies. All the antibodies were used at different dilutions 






2.2.3.3. Brain homogenates 
 
Homogenization buffer 
0.32 M sucrose  
1 mM NaHCO3 
 
To make brain homogenates from rats, wild type and knock-out mice, one cortex 
was transferred to glass Teflon homogenizer and homogenized using 1.5 ml of 
homogenization buffer with freshly added protease inhibitor cocktail and Benzonase 
(sigma). Homogenization is performed by giving 10 strokes at 1200rpm on ice. The 
protein concentration was determined by BCA assay. 
2.2.3.4. Determination of Protein concentration by BCA assay 
 
Protein concentrations were determined using BCA (Bicinchoninic acid) assay kit 
(Pierce). Under alkaline conditions, Bicinchoninic acid protein assay relies on the 
formation of a Cu2+ protein complex followed by reduction of the Cu2+  to Cu1+ ( 
purple-blue complex). The amount of reduction is proportional to the amount of 
protein present. The assay was performed using the manufacturer’s protocol.  
 




5mM HEPES  
Protease inhibitors (PMSF, Final concentration 200mM/Pepstatin (Final concentration 
1µg/ml) 
 
4%, 6% and 13% ficoll were made in sucrose buffer. 
 
Prepare the non-continuous ficoll gradient in SW41 tube, from bottom to top: 4ml 
13%, 1ml 9%and 4ml 6% (w/v) ficoll. The 9% and 6% ficoll has to be added very 





bands between different concentrations. One gradient per rat brain is used. 
Decapitate rats (5-6 weeks old) and remove cortex into ice cold sucrose buffer and 
homogenize in 30 ml (for 2 rat brains) sucrose buffer at 900rpm for 9 strokes. 
Centrifuge at 5000 rpm for 2 min at 4°C, in fixed angle SS34 rotor to pellet the cell 
debris. Decant supernatants in to new SS34 tube (S1) and re-centrifuge at 
11,000rpm for 12 min at 4°C. Resuspend pellet (leaving the dark brown part, P2) in 
6ml (3 ml for each gradient) sucrose buffer and collect them in 15 mL Falcon tube. 
Load 3 ml of resuspended pellet onto a Ficoll gradient with pre-cut 1 ml pipette tips. 
Centrifuge at 22,500 rpm, 35 min and 4°C in SW41 rotor. Isolate bands at the 
interfaces between 13% and 9% Ficoll. Dilute the bands with 30 ml sucrose buffer 
containing pepstatin/PMSF in SS34 tubes. Centrifuge for 12 min in SS34 at 11 
000rpm, 4°C to wash the traces of ficoll. Resuspend pellet in 5 ml sucrose buffer 
containing pepstatin/PMSF (2.5 ml per cortex). 
 
2.2.3.6. Binding interactions  
 
Cell Lysis and Co-Immunoprecipitation 
Lysis Buffer 
50 mM Tris-HCl pH 8.0  
150 mM NaCl 
2 mM EDTA 
0.5% NP40  
EDTA free complete protease inhibitor cocktail (Roche) 
 
Cells expressing the protein/s of interest were lysed using appropriate volume of 
lysis buffer with freshly added protease inhibitor cocktail. The cells were scraped, 
collected into eppendorf tubes and incubated on ice for 20-30 mins. After 
incubation, the cell lysate was centrifuged at 4°C for 10 mins and 12000rpm to 
remove the cell debris. The supernatant is transferred into fresh eppendorf tubes 
and used as required. 
The cell lysate (reaction volume of 400µl) was incubated with 4µl of anti-Myc 





Sepharose beads were equilibrated by adding 1ml of lysis buffer, centrifuged at 
3000rpm for 1 min at 4°C  for three times. Equilibrated beads were then added to 
the cell lysates with pre-incubated antibody and incubated for 1 hour to overnight at 
4°C on the shaker. The sepharose beads with the bound proteins and antibody were 
washed three times with 1 ml of lysis buffer at 3000rpm for 1 min each. 30µl of 2X 
sample buffer is added to the samples and boiled at 95°C for 5 mins. The samples 
were analyzed by SDS PAGE and western blotting. 
Immunoprecipitation of Mover with Calmodulin 
Lysis Buffer 
50 mM Tris-HCl pH 8.0  
150 mM NaCl 
4 mM CaCl2 
1% NP40  




50 mM Tris-HCl pH 8.0  
150 mM NaCl 
4 mM CaCl2 
0.1% NP40  
 
4-12% Bis-Tris pre-cast gels (Invitrogen) 
 
20X MES SDS running buffer  
 
50 mM MES 
0 mM Tris Base 
0.1% SDS 




HEK 293T cells grown on 10cm dish were transfected using PEI with GFP-Mover. 
Cells were lysed 48 hours post transfection. The cell lysate (reaction volume of 
400µl) was incubated with 20µg of recombinant human Calmodulin (Enzo) in the 
presence of 4mM Ca2+ over night at 4°C. 4µl of anti-GFP antibody was added and 





were equilibrated by adding 1ml of lysis buffer, centrifuged at 3000rpm for 1 min at 
4°C  for three times. Equilibrated beads were then added to the cell lysates with 
pre-incubated antibody and incubated for 4 hours at 4°C on the shaker. The 
sepharose beads with the bound proteins and antibody were washed three times 
with 1 ml of wash buffer in the presence of Ca2+; centrifuged at 3000rpm for 1 min 
each. 30µl of 2X sample buffer is added to the samples and boiled at 95°C for 5 
mins. The samples were analyzed by SDS PAGE and western blotting. After 
separation, the proteins were blotted on to PVDF membrane (0.2µm) and fixed with 
0.2% glutaraldehyde. PVDF membrane with fixed proteins was blocked using 4% 
milk solution in TBS and probed with anti-GFP and anti-Calmodulin antibodies. 
Interaction of Mover on Munc13 and Calmodulin complex 
Lysis Buffer 
50 mM Tris-HCl pH 8.0  
150 mM NaCl 
2 mM CaCl2 
1% NP40  




50 mM Tris-HCl pH 8.0  
150 mM NaCl 
2 mM CaCl2 
0.1% NP40  
 
4-12% Bis-Tris pre-cast gels (Invitrogen) 
 
20X MOPS SDS running buffer 
 
50 mM MOPS  
50 mM Tris Base 
0.1% SDS  
1 mM EDTA pH 7.7 
 
 
HEK 293T cells grown on 10cm dish were transfected using PEI with Munc13-EGFP. 
Cells were lysed 48 hours post transfection. The cell lysate (reaction volume of 
600µl) was incubated with 30µg of recombinant human Calmodulin (Enzo) in the 





were lysed as described above and 50µl was added to the Munc13-Calmodulin 
complex, incubated overnight at 4°C. 5µl of anti-GFP antibody was added and 
incubated at 4°C for 6-8 hours on the shaker. 30µl of protein G Sepharose beads 
were equilibrated by adding 1ml of lysis buffer, centrifuged at 3000rpm for 1 min at 
4°C  for three times. Equilibrated beads were then added to the cell lysates with 
pre-incubated antibody and incubated for 4 hours at 4°C on the shaker. The 
sepharose beads with the bound proteins and antibody were washed three times 
with 1 ml of wash buffer in the presence of Ca2+; centrifuged at 3000rpm for 1 min 
each. 30µl of 2X sample buffer is added to the samples and boiled at 55°C for 10 
mins. The samples were analyzed by SDS PAGE using 4-12% Bis-Tris gel and 1X 
MOPS running buffer from Invitrogen. After separation, the proteins were blotted on 
to PVDF membrane (0.2µm) and fixed with 0.2% glutaraldehyde. PVDF membrane 
with fixed proteins was blocked using 4% milk solution in TBS and probed with anti-
GFP, anti-Mover and anti-Calmodulin antibodies.  
2.2.3.7. Expression and purification of GST-Mover 
 
Transformation of chemo-competent E. coli 
 
LB-medium 
Chemo-competent XL1-BLUE, Rosetta 
Bacterial agar plates 
 
Chemo-competent cells were thawed on ice for 15 mins. 0.5-1µg of DNA was added 
to a 100μl cell aliquot and incubated for 30 Min on ice. Cells were heat shocked for 
45s at 42 °C and immediately cooled on ice for 1 min. 200μl LB medium was added 
and cells were incubated for 45-60 Min at 37 °C on a horizontal shaker. The 
bacterial-DNA mixture was plated on bacterial agar plates and incubated over night 










Electro-competent cells were thawed on ice for 15 mins. 0.5-1µg of DNA was added 
to a 40μl cell aliquot and transferred into ice-cold cuvette. Cells were treated by 
electric shock using a micropulser (Bio-Rad) and 1ml 0f SOC medium was added, 
and incubated for 45-60 min at 37 °C on a horizontal shaker. 200µl of bacterial-DNA 
mixture was plated on agar plates with appropriate antibiotic and incubated over 
night at 37 °C. 
Liquid cultures of bacteria 
 
Small scale liquid cultures 
A single colony was inoculated into 3 ml LB medium supplemented with the 
appropriate antibiotic and incubated over night at 37 °C and 250rpm in a shaker. 
The bacterial culture was used for small scale DNA preparation (Mini Prep). 
 
Large scale liquid cultures 
For large scale DNA preparation (Maxi Prep) and protein purification, a single colony 
was inoculated into 2-3 ml of LB medium supplemented with appropriate antibiotic 
to prepare a starter culture and incubated for 6-8 hours at 37°C and 250rpm in a 
shaker. Starter culture was inoculated into 200 ml LB-medium supplemented with 
the appropriate antibiotic, and incubated over night at 37 °C and 250rpm. 
 
Purification of GST-Mover 
LB medium 



















150mM potassium acetate 
10mM Glutathione 





Transform Rosetta 2 BL21 cells with GST-Mover using electroporation 
transformation protocol as descried earlier. A single colony was inoculated into 5ml 
of LB medium, incubated over night at 37°C and 220rpm.Next day, inoculate the 
overnight culture into 500ml LB medium and shake at 37°C until an OD600nm of 
0.5 is reached. Add 1mM IPTG and shake the culture at 20°C and 150rpm for 24h. 
Harvest the bacterial culture by centrifugation at 4°C and 4000rpm for 25 mins. 
Resuspend the bacterial pellet in 20ml of lysis buffer with freshly added protease 
inhibitors. Cells were disrupted by sonicating three times on ice for 15 sec with 
intervals. The cell lysate was centrifuged at 12000rpm for 70 mins. 1 ml of 
glutathione sepharose beads were equilibrated by adding 1ml of lysis buffer, 
centrifuged at 4000rpm for 5 min at 4°C  for three times. Equilibrated beads were 
then added to the cell lysate and incubated overnight at 4°C on the shaker. The 
sepharose beads with the bound protein was washed three times with 5 ml of lysis 
buffer and centrifuged at 4000rpm for 5 min each. The glutathione sepharose-bound 
protein was eluted by adding 1-5 ml of elution buffer at RT for 30 mins-1 hr on a 
shaker and centrifuged at 4000rpm for 5 mins. The eluted protein is dialyzed 
against 1X PBS over night at 4°C using a dialysis membrane of MW cut off 6-8 kDa 
(Omni lab). The dialyzed protein is concentrated using a spin-X-UF concentrator 
(Corning) by centrifuging at 5000 rpm for 10 mins. The protein estimation is done 
using Nanodrop.  
 




20 mM Tris-HCl (pH 7.5),  
10 mM MgCl2,  
0.5 mM DTT, 0.1 mM EDTA, 





2 mM CaCl2, 
100 µM ATP  
 
To observe the effect of Mover on the phosphorylation of CaMKII (Ca2+- Calmodulin 
dependent protein kinase) - a target of Calmodulin, an in vitro phosphorylation 
assay of CaMKII was performed with varied concentrations of Mover (from 1, 2, 5 
and 10 molecules) and GST as a control. But the concentrations of CaMKII and 
Calmodulin were kept constant.  The reaction was executed in the reaction buffer 
with 25 ng of recombinant CaMKII with 1, 5 and 10 molecules of purified GST-Mover 
to one molecule of recombinant human Calmodulin (Enzo), incubating the reaction 
at 30 °C for 30 min in the presence of 2mM Ca2+. The proteins were concentrated 
using 50% TCA and suspended in 2 X SDS-PAGE sample buffers and incubated at 
55 °C for 5 mins. The proteins were resolved by SDS-PAGE were transferred to 
PVDF membranes. Resolved proteins were detected by immunoblotting with 
respective antibodies- anti- Mover, anti-CaM and anti-CaMKII. Two CaMKII 
antibodies were used- one that detects phosphorylated CaMKII and the other 
dephosphorylated form of CaMKII. 
 
2.2.4. Molecular biology 
2.2.4.1. Cloning 
 
cDNA's of Mover deletion constructs were synthesized by Genscript and provided in 
PUC vector. The cDNA's were digested with the appropriate restriction 
endonucleases (Fermentas Fast Digest and New England Biolabs) and the reaction 
incubated at 37°C from 30 mins-6 hrs depending on the requirement. The general 
digestion reaction was set up accordingly 
Fast digest green buffer or NEB 10X  2µl 
Restriction enzymes    1µl 
DNA       10µg 
Water       make it to 20µl 
The cleaved products of DNA were analyzed by agarose gel electrophoresis. 





The digested DNA samples were analyzed by agarose gel electrophoresis. 
Depending on the size of the cleaved products, an appropriate percentage of 
agarose is chosen as the separation is based on the concentration of the agarose. 
The smaller the percentage of agarose the larger the size of the DNA fragments 
resolved. Appropriate percentage of agarose is weighed and boiled with 1X TAE 
buffer in a microwave oven until a clear transparent solution is reached. Then 4-5µl 
of Ethidium bromide or Midori green is added to agarose that helps in visualizing the 
DNA fragments on the gel upon exposure to ultraviolet light. The required 
fragments of DNA are cut using a scalpel and transferred to eppendorf tubes for 
purification. The purification of DNA from agarose gel is done using a purification kit 
from Promega following manufacturer's protocol. 
Ligation 
Digested DNA was ligated into the appropriate linearized plasmid DNA by using T4-
DNA ligase (NEB). T4-DNA ligase is an enzyme that catalyzes the formation of a 
phosphodiester bond between juxtaposed 5' phosphate and 3' hydroxyl termini in 
duplex DNA. The plasmid DNA and the insert DNA were used in the ratio of 1:2 to 
1:5 respectively. Ligation reaction was done as follows: 
 
Linearized vector      25ng 
10X T4 DNA-ligase ligation buffer    1µl 
insert DNA       100ng 
T4-DNA Ligase      0.5µl   
Nuclease-free water     to 10µl 
 
The ligation reactions were incubated at 16°C overnight and heat inactivated the 
enzyme at 65°C for 10 mins. 1-5µl of the ligation mixture was used for 
transformation. 
2.2.4.2. Mini and Maxi preparation of DNA 
A Single colony was inoculated into 3 ml (mini) or 200 ml (maxi) LB medium with 
appropriate antibiotic and plasmid DNA was isolated using Qiagen endofree Mini 





2.2.4.3. Determination of DNA concentrations using 
spectrophotometer 
 
Concentrations of DNA were measured using a spectrophotometer (Eppendorf). DNA 
was diluted to 1:20 in water for measurement. The purity of DNA was verified by 
looking at the absorbance ratio at 260nm/280nm that is supposed to be 1.8. 
2.3. Generation of Mover knock-out mouse line 
 
Conditional targeting vector harboring Exons 1 to 3 of Mover flanked by lox sites 
was generated by Polygene.  The targeting vector was electroporated into 129Ola 
ES-cells. After screening, four ES cell clones harboring the conditional targeting 
vector of Mover were provided by Polygene. All the documentation provided by 
Polygene is maintained in the lab.  
2.3.1. ES Cell culture and DNA extraction 
 
ES cells were maintained on inactivated MEFs. First, MEFs were taken into culture 
with MEF medium. The confluent MEFs were inactivated using Mitomycin C for the 
maintenance of ES cells. Mover ES cell clones were taken into culture with 
inactivated MEFs. The confluent ES cells were split and plated onto a 6-well plate to 
extract DNA for genotyping. 
 
MEFs into culture 
MEF medium  
500 ml  KO-DMEM  (GIBCO 10829-018) 
 95 ml   FCS   (HyClone SH30070-03) 
 6 ml   MEM   (GIBCO 11140-035) 
 6 ml   Glutamine  (GIBCO 25030-024) 
 6 ml   2-Mercaptoethanol (SIGMA M7522) diluted! 
    (7.2 µl 14 M - 99% - in 10 ml PBS, filter sterilize;   
            PAA H15-002) 
 3ml   Pen/Strep  (GIBCO 15140-122) 
 





Wash cells once with 15 ml PBS. Add 2 ml of 0.05% Trypsin-EDTA (GIBCO 
25300-054) and incubate for 5 min at 37°C. Stop digestion with 7 ml medium, 
triturate cells carefully (9 ml) and add 3 ml of cell suspension to each precoated 
T75 flask containing 12ml medium. Move T75 flask with MEFs to distribute the 
cells. 
Inactivation of MEFs 
MEFs were inactivated using Mitomycin C (SIGMA M0503-2MG) as follows: dissolve 
2 mg Mitomycin C in 4 ml PBS (50x stock) and add 300 µl 50x Mitomycin C (final 
concentration: 1x) incubate for 2 hrs at 37°C and 5% CO2. Wash cells twice with 
PBS and add MEF medium (15 ml), incubate at least for 2 hrs and then split 
inactivated MEFs using the protocol used for splitting MEFs and plate on to 6-well 
plates.  
 
Maintenance of ES cells on inactivated MEFs 
ES cell medium  
500 ml  KO-DMEM  (GIBCO 10829-018) 
 95 ml   FCS   (HyClone SH30070-03) 
    6 ml  MEM   (GIBCO 11140-035) 
    6 ml  Glutamine  (GIBCO 25030-024) 
    6 ml  2-Mercaptoethanol (SIGMA M7522) diluted! 
    (7,2 µl 14 M - 99% - in 10 ml PBS, filter sterilize;   
            PAA H15-002) 
3 ml   Pen/Strep  (GIBCO 15140-122) 
65 µl    LIF (ESGRO Millipore ESG 1107) 
 
Exchanged the MEF medium from inactivated MEFs with ES cell medium and four 
Mover ES cell clones were taken into culture.ES cells were confluent and have been 
split at 1:3 ratio as follows: wash the cells with 5 ml PBS. Add 1 ml 0.25% trypsin 
(GIBCO 25200-056) and incubate for 8 min at 37°C. Stop digestion by adding 5 ml 
ES cell medium triturate the cells carefully and distribute into the wells. Following 








DNA preparation from ES cells 
 
ES cells from the 6 well plate without MEFs were used for the extraction of DNA. 
Following protocol was followed: wash the cells with 5 ml PBS. Add 1 ml 
0.25%trypsin and incubate for 8 min at 37°C. Stop digestion by adding 5 ml ES 
medium and triturate the cells carefully. Collect cell suspension and centrifuge at 
800 rpm for 5 min. Resuspend cell pellet in 1 ml of ES cell medium and make two 
aliquots in E-cups. Centrifuge at 800 rpm for 5 min and DNA was extracted using 
the DNeasy Blood & Tissue Kit from QIAGEN. 
 
2.3.2. Microinjection, Mouse breeding and Genotype analysis 
 
The amplified ES cell clones (2B11 and 1F10) were injected into blastocysts of 
C57/BL6 mice to generate chimeric mice. Genotyping was done to identify the 
chimerism by using PCR protocol I and II. The obtained chimeric mice were bred 
with Rosa Flip mice to remove the Frt-flanked neo expression cassette and verified 
by using PCR protocol III. At this stage the mice have a Mover gene that is flanked 
by loxp sites, hence called as ‘flox mice’. These mice were genotyped for the 
presence of lox allele using the PCR protocol I. In order to obtain heterozygous 
Mover mice, the flox mice were bred with heterozygous Cre mice and the obtained 
progeny was verified for the Cre positive heterozygous Mover mice using the PCR 
protocol IV and finally the heterozygous mice were inbred to generate global Mover 
knock-out mice. Global Mover knock-out mice were verified by genotyping using a 





Fig.2.1. Schematic overview of the generation of Mover knock-out mice. Wild 
type and modified Mover gene with 5' and 3' loxp sites (in green triangles) and neo cassette flanked by Frt sites (in 
black triangles). Forward and reverse for genotyping are labeled. 
 
PCR protocol I 
To identify 5’ lox sites PCR conditions 
DMSO 1µl   95°C 03:00   
DNA 1µl   95°C 00:30   
B008-P3 1µl 5pmol/µl 55°C 00:30   
B008-P4 1µl 5pmol/µl 69.2°C 00:30 goto 2 for 40X 
H2O 8.5µl   69.2°C 01:00   
2X MM 12.5µl   4°C pause   





Wt allele 234bp 













PCR protocol II 
 
To identify 3’ lox sites PCR conditions 
DMSO 1µl   95°C 03:00   
DNA 1µl   95°C 00:30   
28816 1µl 5pmol/µl 57°C 00:30   
28817 1µl 5pmol/µl 69.2°C 00:30 go to 2 for 40X 
H2O 8.5µl   69.2°C 01:00   
2X MM 12.5µl   4°C        pause   
      
28816 GGATCCAGATTTAAGGCCTTG 
28817 CGACTCACTAGTGGGCAGATC 
Expected bands- Lox 213bp 
 
PCR protocol III 
 
To identify the presence 
and absence of neo 
PCR conditions 
DMSO 1µl   98°C 03:00   
DNA 1µl   98°C 00:30   
28816 1µl 5pmol/µl 55°C 00:30   
4174 1µl 5pmol/µl 72°C 00:30 go to 2 for 35X 
H2O 8.5µl   72°C 10:00   
2X MM 12.5µl   10°C pause   
       
28816  GGATCCAGATTTAAGGCCTTG 




Without neo no band 
 
PCR protocol IV 
 
To identify the 
presence of Cre  
PCR conditions 
DMSO 1µl   95°C 03:00   
DNA 1µl   95°C 00:30   
24365 1µl 5pmol/µl 61°C 00:30   
24366 1µl 5pmol/µl 72°C 00:30 go to 2 for 35X 
H2O 8.5µl   72°C 07:00   
2X MM 12.5µl   4°C pause   
       
24365GCG GTC TGG CAG TAA AAA CTA TC 
24366   GTG AAA CAG CAT TGC TGT CAC TT 
Expected bands- 
  
Cre positive 100bp 






PCR protocol V 
To identify the 
presence of Wt and lox 
alleles 
PCR conditions 
DMSO 1µl   95°C 03:00   
DNA 1µl   95°C 00:30   
B008-P3 1µl 5pmol/µl 55°C 00:30   
 1µl 5pmol/µl 69.2°C 00:30 go to 2 for 40X 
H2O 8.5µl   69.2°C 01:00   
2X MM 12.5µl   4°C        pause   





Wt allele 234bp 
267bp Lox allele 
 
Multiplex PCR protocol VI 
To identify the knock-
out allele 
PCR conditions 
DMSO 1µl   98°C 03:00   
DNA 1µl   98°C 00:30   
B008-P4 1µl 5pmol/µl 55°C 00:30   
E-4001 1µl 5pmol/µl 72°C 00:30 go to 2 for 35X 
E-3001 1µl   72°C 10:00   
H2O 7.5µl  10°C pause  
2X MM 12.5µl       
       
B008-P4 CCAATCACAAGGCGAACGAG 
E-3001    CATTCAGTGGGACAAGCAGA 

















3.1. Tprg, a homologue of Mover  
 
Mover shares homology with Tprg (Transformation-related protein 63regulated), a 
gene predominantly expressed in skin, and Mover is also known as Tprgl or Tprg1-
like (Antonini et al., 2008). Mover/Tprgl/Tprg1-like protein shares 49% amino acid 
identity with Tprg protein. Exogenous expression of Mover-mGFP produced a 
punctate pattern in 14DIV cultured hippocampal neurons. Unexpectedly, the 
expression of Tprg-mGFP also showed punctate fluorescence pattern in cultured 
neurons. Both recombinant Mover and recombinant Tprg punctae co-localize with 
endogenous Synaptophysin indicating their accumulation at synapses (Figure 3.1.1; 
A). Although, no expression of Tprg was reported in the brain, the recombinant 
version of Tprg was still targeted to presynaptic terminals. Because Mover has a 
strong tendency to dimerize Mover may also heterodimerize with TPRG, and this 
may affect presynaptic targeting of both proteins. I tested heterodimerization by a 
co-immunoprecipitation assay from Hek293T cell lysates co-expressing Mover-myc 
along with recombinant GFP-Mover or recombinant Tprg-mGFP. The proteins were 
immunoprecipitated with ant-myc antibody and analyzed by SDS-PAGE and western 
blotting. The western blot is probed for anti-GFP antibody that detected the GFP-
tagged proteins of Mover and Tprg. Recombinant Mover and recombinant Tprg failed 
to heterodimerize in vitro (Fig.3.1.2; A). Failure to heterodimerize with Mover 
indicates that Mover and Tprg are two different proteins that may have different 
roles to play. I also used expression of recombinant Mover-mGFP and TPRG-mGFP 
in Hek293T cells to test the specificity of antibodies against these two proteins. 
Lysates from HEK cells expressing GFP-Mover, Mover-mGFP and Tprg-mGFP were 
analyzed by SDS-PAGE and immunoblotted against anti-GFP, anti-Mover and anti-
Tprg antibodies. The antibodies showed specificity for respective recombinant 






















B.      C. 
 
Fig.3.1.1. Mover-mGFP and Tprg-mGFP accumulate at presynaptic sites. 
Expression of C-terminal mGFP-tagged Mover and Tprg showing a punctate fluorescence pattern in 14DIV cultured 
hippocampal neurons. Inlay is shown as higher magnification images (left to right) of the construct (green), 
endogenous Synaptophysin (red) and merge (along with   MAP2). Scale bar: 10μm for grey panel and 2µm for higher 
magnification images (A).Bar graph representing the enrichment of Mover-mGFP and Tprg-mGFP at presynaptic 
sites. Fluorescence intensities ratio were measured for Mover-mGFP and Tprg-mGFP synaptic puncta to the 
intervening axonal regions. Enrichment of Mover-mGFP at presynaptic sites is statistically significant from Tprg-
mGFP.t-test. P≤ 0.005 (**). N=2 (B). Bar graph illustrates the percentage of co-localization of Mover-mGFP and Tprg-
mGFP puncta with endogenous Synaptophysin. No statistical significance is observed in the co-localization of Mover-
mGFP and Tprg-mGFP puncta with Synaptophysin (C).  
  
Enrichment of Mover-mGFP and Tprg-mGFP at presynaptic sites was determined by 
measuring fluorescence intensities of synaptic puncta along the axon to the 
intervening axonal regions (synaptic versus non-synaptic). Presynaptic targeting 
capacity of Mover-mGFP showed a two fold increase to that of Tprg-mGFP 
(Fig.3.1.1; B). No statistical difference was observed in the percentage of co-





















Fig.3.1.2. Tprg does not heterodimerize with Mover in vitro. GFP-Mover was 
immunoprecipitated with co-expressed Mover-myc from HEK293T cell lysates. Tprg-mGFP does not IP with Mover-
myc. Protein complexes were immunoprecipitated using sepharose coupled antibodies against myc epitope .L= Total 
lysate, IP= immunoprecipitate.(A).Specificity of Mover and Tprg antibodies.HEK293T cells lysates expressing GFP-
Mover, Mover-mGFP and Tprg-mGFP were analyzed by SDS-PAGE and western blotting. The blot was probed with 







3.2. Presynaptic targeting of Mover 
 
Mover has been identified as a Bassoon binding partner in yeast-2-hybrid assay, 
using C-terminal region of Bassoon as a bait (Kremer et al, 2007).It has been 
identified as a peripheral membrane protein associated with synaptic vesicles 
(Ahmed et al, 2013). Structurally and functionally nothing is known about Mover. 
Mover has no homology domains except for a HSac2 domain spanning aa53-163 
and a predicted Calmodulin binding site between aa206-218. HSac2 domain belongs 
to family of inositol phosphatases (Minagawa et al., 2001) and functions as inositol 
phosphate-5 polyphosphatase. Inositol phosphatases are involved in several 
functions such as synaptic vesicle recycling and actin polymerization. Data base 
analysis suggests that the Mover gene is alternatively spliced producing two 
isoforms, a long isoform harboring exons 1-4 and a short isoform lacking exon2 
(aaΔ93-151). In the current study, I aimed to characterize the functional domains 
of Mover mediating cellular properties such as presynaptic targeting, self-interaction 
and potentially affecting synaptic vesicle recycling. Expression of recombinant N-
terminal GFP-tagged full length Mover generated aggregates in cultured 
hippocampal neurons (Appendix Fig.7.1), thus making it difficult to study. 
Therefore, full length constructs with C-terminal tags and several deletion mutants 
of Mover fused with either N-terminal GFP or C-terminal mGFP were generated to 
identify the domains required for presynaptic targeting and self-interaction of 
Mover. Fig.3.2. shows the list of all deletion mutants used in the current study. 
In general, deletions were introduced to generate constructs encoding 
 aa52-266 and aa91-266  
 aa 52-253 and aa 53-163 (the latter encoding the HSac2 homology 
domain)  







Fig. 3.2. List of Mover deletion mutants used in the current study. Schematic 
representation of full length and the deletion mutants of Mover fused with either N-terminal GFP or C-terminal mGFP 
used in the current study. Deletion constructs also include the predicted HSac2 (aa53-163) and a construct with a 
point mutation in the predicted Calmodulin binding site (aa206-218. F206R). In addition mutations at predicted 
phosphorylation sites threonine 13, 64 and tyrosine 257. Mover amino acid sequence is represented in blue boxes 
and the crosshatched boxes indicate deleted regions. Point mutations are indicated with amino acid number. The 






3.2.1. Localization of GFP-VAMP (Vesicle Associated Membrane 
Protein) to presynaptic sites. 
 
VAMP or Synaptobrevin is a synaptic vesicle associated membrane protein that is 
part of the SNARE complex. The SNARE complex mediates fusion of synaptic 
vesicles with the plasma membrane. I used recombinant VAMP fused with N-
terminal GFP as a typical example of presynaptic targeting in cultured hippocampal 
neurons. Expression of GFP-VAMP produced punctate fluorescence along the axon 
with minimal signal detected between intervening axonal regions (Fig 3.2.1; A). 
These puncta co-localize with endogenous Synaptophysin indicating the 
accumulation of GFP-VAMP at presynaptic sites.  
A. 
 
Fig.3.2.1. Localization of GFP-VAMP to presynaptic sites. Localization of GFP-tagged 
VAMP in 14DIV cultured hippocampal neurons and immunostained for endogenous Synaptophysin (SyPhy) (in red), a 
presynaptic marker and MAP2 (in blue), a dendritic marker. Higher magnification images of the inlay are shown in 
individual channels (from left to right) - over-expressed protein in green, Synaptophysin in red and a merge along with 
MAP2. GFP-VAMP puncta positive for Synaptophysin are shown with arrow heads. Scale bar: 10μm for white panel 






3.2.2. Localization of Mover deletion mutants in cultured 
hippocampal neurons. 
 
The regions or amino acid sequences necessary for the presynaptic targeting of 
Mover were unknown. Expression of mGFP tagged full length recombinant Mover 
(Mover-mGFP) and the N-terminal deletion mutant of aa51 (52-266-mGFP) in 
cultured neurons produced punctate fluorescence along the axon. These puncta co-
localize with endogenous Synaptophysin indicating the localization of Mover at 
presynaptic sites (Fig.3.2.2.1; A). In order to compare the presynaptic targeting of 
full length Mover-mGFP and 52-266-mGFP, fluorescence intensities of synaptic 
puncta and intervening axonal regions (non-synaptic regions) were measured using 
Metamorph image analysis software.  Full length Mover-mGFP and 52-266-mGFP 
showed no significant difference in their targeting capacity to presynaptic terminals 
(Fig.3.2.2.1; B). No significant difference was observed in the percentage of co-
localized Mover-mGFP puncta and 52-266-mGFP puncta with Synaptophysin (Fig 
3.2.2.1; C).Co-localization analysis with Synaptophysin was performed using Puncta 
Analyzer program written by Bary Wark (Ippolito and Eroglu, 2010). Expression of 
several mGFP tagged deletion mutants each showed a diffuse distribution along the 
axon with weaker expression. These mutants included a construct encoding the 
predicted HSac2 domain (aa53-163), a construct lacking the part encoded by 
exon2, a construct lacking the N-terminal 91 amino acids, and a construct lacking 
both the N-terminal 51 and the C-terminal 13 amino acids (aa52-253). This 
indicates that N-terminal, C-terminal and central deletions are each required for 
targeting (Fig 3.2.2.2; and Fig. 3.2.2.3.) only the N-terminal 51 amino acids are not 
necessary for the presynaptic targeting of Mover. In particular, regions between 
aa52-90, aa253-266, aa53-163 (HSac2) and aa93-151 (exon2) are necessary for 
















B.      C. 
 
Fig.3.2.2.1. The deletion mutant 52-266-mGFP targets to presynaptic 
terminals. Expression of mGFP-tagged full length Mover and the deletion mutant lacking N-terminal aa51 
showing a punctate fluorescence pattern in14DIV cultured hippocampal neurons. Mover-mGFP and 52-266-mGFP 
puncta co-localize with Synaptophysin (SyPhy). Inlay is shown as higher magnification images (left to right) of the 
construct (green), endogenous Synaptophysin (red) and merge image (along with MAP2 in blue). Scale bar: 10μm for 
grey panel and 2µm for magnified images (A) Presynaptic targeting of  full length Mover and 52-266 deletion mutant 
of Mover. Average fluorescence intensities of the synaptic puncta were measured for full length Mover-mGFP, 
deletion mutant of aa51 (52-266-mGFP) and GFP-VAMP. No statistical difference in the targeting of Mover-mGFP 
and 52-266 deletion mutants at the presynaptic sites was observed (B). Co-localization analysis of full length and 52-
266 deletion mutant of Mover with Synaptophysin in comparison to GFP-VAMP(C). No significant difference either in 
their targeting or co-localization with Synaptophysin was observed between full length and deletion mutant (52-266) of 
Mover compared to GFP-VAMP. One way ANOVA with Bonferroni’s posthoc test. Values represented as 
mean±SEM. 
 
Deletion mutants with N-terminal GFP tag did not produce any difference in the 
targeting of Mover when compared to the mutants with C-terminally tagged mGFP.  
Similar to the targeting of deletion mutants with C-terminal mGFP tag, expression of 
deletion mutants with N-terminal GFP tag - aa91-266, aa52-253, HSac2 domain 
(53-163), short isoform ( excluding the expn 2 region spanning aa93-151) displayed 









Fig.3.2.2.2. Δ93-151-mGFP and 53-163-mGFP do not target to presynaptic 
sites. Localization of mGFP-tagged deletion mutant lacking exon 2 region (Δ93-151-mGFP) and the other 
encoding the predicted HSac2 domain  (53-163-mGFP) show diffuse labeling along the axon. Co-stained with 
Synaptophysin (SyPhy) and MAP2. Higher magnification images of the inlay are shown in individual channels (from 
left to right) - over-expressed protein in green, Synaptophysin in red and a merge along with MAP2 (in blue). Scale 







Fig.3.2.2.3. Diffuse distribution of 52-253-mGFP and 91-266-mGFP deletion 
mutants of Mover. Neurons expressing 52-253 and 91-266 with a C-terminal mGFP tag were diffusely 
distributed along the axon in 14DIV cultured hippocampal neurons. Co-stained for Synaptophysin (SyPhy, in red) and 
MAP2 (in blue).Higher magnification images of the inlay are shown in individual channels (from left to right) - over-
expressed protein in green, Synaptophysin in red and a merge along with MAP2 in blue. Scale bar: 10μm for grey 





3.3. Self-interaction of Mover 
 
Yeast 2-hybrid assay suggests that full-length Mover undergoes self-interaction 
(Ahmed et al., 2013). The amino acid sequences or regions necessary for Mover to 
undergo self-interaction are unknown. The yeast 2-hybrid data that full length 
Mover undergoes self-interaction was further corroborated with a co-
immunoprecipitation assay. Hek293T cell lysates co-expressing GFP-Mover and 
Mover-myc were immunoprecipitated using sepharose or agarose coupled antibodies 
against myc tag. Immunoprecipitated complexes were analyzed by SDS-PAGE and 
western blotting.  
 
The deletion mutants used for identifying the regions required for the presynaptic 
targeting of Mover were also used to test for their role in self-interaction. N-terminal 
GFP-tagged deletion mutants of Mover encoding aa52-266, aa 91-266, aa52-253, 
the HSac2 domain (53-163), or lacking the central exon2 region (lacking 93-151) 
were co-expressed with Mover-myc in Hek293T cells. The cell lysates with the 
respective GFP-deletion mutant along with Mover-myc were immunoprecipitated 
using sepharose coupled antibodies against myc tag. All the deletion mutants failed 
to dimerize in vitro except for GFP-52-266. Thus, co-immunoprecipitation 
experiments with GFP-deletion mutants identified the regions between aa52-90, 
aa253-266, aa53-163 (HSac2) and aa 93-151 (exon2) to be necessary for Mover to 
undergo self-interaction in vitro (Fig. 3.3; A and B).    
 
Interestingly, the regions or amino acid sequences required for self-interaction of 
Mover were also found to be necessary for the presynaptic targeting of Mover. All 
the deletion mutants that impaired presynaptic targeting of Mover also failed to 
dimerize in vitro, suggesting dimerization /oligomerization of Mover as a 
















Fig.3.3. Deletion mutants- GFP-52-253, GFP-53-163, GFP- Δ93-151 and 
GFP-91-266 fail to dimerize in vitro. GFP-Mover and GFP-52-266 were pull-down with Mover-myc 
co-expressed in HEK293T cells using an anti-myc antibody. Mover-myc. Protein complexes were immunoprecipitated 
using sepharose beads coupled antibodies against myc epitope (A).GFP-52-253, GFP-Δ93-151, GFP-53-163 and 
GFP-91-266 were not immunoprecipitated upon pull-down with anti-myc antibody. Protein complexes were 
immunoprecipitated using sepharose coupled antibodies against myc epitope.  Immunoprecipitated pellets were 
analyzed by SDS-PAGE and detected through western blotting by probing against anti-GFP and anti-Mover (A). L= 









Table 1. Illustrating the deletion mutants and the regions required for presynaptic 
targeting and self-interaction of Mover 
 
3.4. Phosphorylation of Mover 
3.4.1. Presynaptic targeting of Mover with mutations at predicted 
phosphorylation sites 
 
Neurotransmitter release is modulated through second-messenger mediated 
signaling pathways resulting in phosphorylation of proteins by protein kinases and 
phosphatases (Leenders and Sheng, 2005). Protein phosphorylation plays an 
important role in pre-and post-synaptic plasticity. Most of the proteins involved in 
multiple steps of exocytotic release machinery are found to be regulated by 
phosphorylation. Phosphorylation of proteins has been shown to be necessary for 
various forms of synaptic plasticity (Turner et al., 1999). 
Mass spectrometry analysis of presynaptic proteins detected a threonine 
phosphorylation site at amino acid 13 of Mover. Bioinformatical analysis also 
suggested additional predicted phosphorylation sites at aa14 (Serine), aa64 












Fig. 3.4.1.1. Targeting of Mover-mGFP to presynaptic terminals. Mover protein 
with  predicted phosphorylation sites (A) Single point mutations introduced at phosphorylation sites threonine 13 and 
64 and at tyrosine 257 (B). Expression of recombinant full length Mover tagged with C-terminal monomeric GFP 
(mGFP) showing a punctate pattern in 14DIV cultured hippocampal neurons. Higher magnification images of the inlay 
are shown in individual channels (from left to right) - over-expressed protein in green, Synaptophysin in red and a 
merge along with MAP2 in blue. Mover puncta co-localizing with Synaptophysin are pointed with arrow heads. Scale 








Fig.3.4.1.2. Point mutations at phosphorylation site-threonine 13 do not 
affect presynaptic targeting of Mover. Expression of C-terminally tagged full length Mover- 
mGFP with a point mutation at threonine 13 to aspartate (T13D-mGFP) or alanine (T13A-mGFP)in 14DIV cultured 
hippocampal neurons display a punctate pattern. Puncta co-localizing with synaptophysin are indicated with arrow 
heads. Higher magnification images of the inlay are shown in individual channels (from left to right) - over-expressed 
protein in green, synaptophysin in red and a merge along with MAP2 in blue. Scale bar: 10μm for grey panel and 2µm 






Here I expressed constructs mutated at predicted phosphorylation sites rendering 
them non-phosphorylatable by changing threonine to alanine, and tyrosine to 
phenylalanine, or phosphomimetic by changing threonine to aspartate. mGFP 
tagged versions of phospho-mutants T13A-mGFP, T64A-mGFP, Y257F-mGFP and full 
length Mover-mGFP were immunostained with anti-GFP, anti-Synaptophysin and 
anti-MAP2 after their expression for 14DIV in cultured neurons. Expression of full 
length mGFP tagged Mover (Fig.3.4.1.1; C), single phospho-mutant at T13A and a 
phospho mimetic mutation at T13D in cultured hippocampal neurons produced 
discrete punctae along the axon that co-localize with endogenous Synaptophysin  
(Fig.3.4.1.2; A) Thus, phosphorylation mutations at site threonine 64 and tyrosine 
257 do not impair presynaptic targeting in 14DIV cultured neurons (Fig.3.4.1.3.; A). 
Single point mutations at phosphorylation sites threonine 13, 64 and tyrosine 257 
had no effect on the presynaptic targeting of Mover. I next tested whether double 
mutations at threonine 13 and threonine 64 (T13A-T64A) as well as threonine 13 
with tyrosine 257 (T13A-Y257F) had any effect on the presynaptic targeting of 
Mover. Both constructs produced a punctate staining pattern and co-localized with 
Synaptophysin puncta, suggesting that presynaptic targeting was not impaired 
(Fig.3.4.1.4; A) 
In order to analyze presynaptic targeting quantitatively, the fluorescence intensities 
of the synaptic punctae (puncta that co-localize with Synaptophysin) were 
measured using Metamorph analysis software. No significant difference in the 
presynaptic targeting capacity of single or double phospho-mutants of Mover was 
observed compared to full length Mover (Fig.3.4.1.4; B and C). Similarly, no 
significant difference in the percentage of co-localization with Synaptophysin has 
been observed between full length Mover and either the single or double phospho-











Fig.3.4.1.3. Point mutations at phosphorylation site threonine 64 and 
tyrosine Y257 do not affect presynaptic targeting of Mover. Expression of C-
terminally tagged full length Mover- mGFP with a point mutation at threonine 64 to alanine (T64A-mGFP) and at 
tyrosine 257 to phenylalanine (Y257F-mGFP) 14DIV cultured hippocampal neurons display a punctate pattern. 
Expression of mGFP-tagged double mutated Mover at T64 (T64A), and Y257 (Y257F) in 14DIV cultured hippocampal 
neurons displaying a punctate pattern. Synaptic puncta are indicated with arrow heads. Higher magnification images 
of the inlay are shown in individual channels (from left to right) - Over-expressed protein in green, Synaptophysin in 













B.      D. 
 




Fig.3.4.1.4. Double point mutations at threonine 13 along with T64 and 
Y257 do not affect presynaptic targeting of Mover. Expression of C-terminally tagged full 
length Mover- mGFP with  a point mutations at threonine 13 and 64 to alanine (T13A-64A-mGFP) and; at threonine 
13 to alanine and tyrosine 257 to phenylalanine (T13A-Y257F-mGFP) 14DIV cultured hippocampal neurons display a 
punctate pattern.  Higher magnification images of the inlay are shown in individual channels (from left to right) - Over-
expressed protein in green, Synaptophysin in red and a merge along with MAP2 in blue. Scale bar: 10μm for grey 
panel and 2µm for small black panels (A). Bar graph representing the presynaptic targeting capacity of single and 
double phospho-mutants compared to Mover-mGFP (B & C). No difference in the presynaptic targeting of Mover-
mGFP and any of the phospho-mutants either single or double (T13D, T13A, T64A, Y257A, T13-T64A and T13A-
Y257A) was observed. Co-localization analysis and phospho-mutants of Mover with synaptophysin in comparison to 






The presynaptic targeting of phospho-mutants of Mover could be due to formation 
of dimers by the over-expressed Mover or with endogenous Mover in cultured rat 
neurons. In order to exclude the effect of dimerization/self-interaction on the 
phosphorylation of Mover, a Mover knock-out mouse line has been generated. 
Expression of phospho-mutants in Mover knock-out mice cultures would not be 
confounded by binding of these mutant variants to an intact endogenous protein. 
 
3.4.2. Self-interaction of phospho-mutants of Mover 
 
From the targeting and self-interaction experiments, it had become clear that the 
regions or sites identified for Mover to undergo self-interaction were also necessary 
for presynaptic targeting of Mover. Hence, I tested whether the phospho-mutants 
dimerize with full length Mover in vitro. Hek293T cell lysates co-expressing either of 
the mGFP-tagged phospho mutants (T13A, T64A, Y257F, T13A-T64A and T13A-
Y257F) and Mover-myc were tested for co-immunoprecipitation with a mouse 
monoclonal anti-myc antibody. Protein complexes were immunoprecipitated with 
sepharose beads against monoclonal antibody and analyzed by SDS-PAGE and 
western blotting. Phospho-mimetic and Mover mutants with either single or double 
mutations at phosphorylation sites and a phospho-mimetic mutation at threonine 13 
did co-immunoprecipitate with Mover-myc, indicating that they are capable of 















Fig.3.4.2. Mutations at phosphorylation sites of Mover had no effect on the 
self-interaction of Mover. GFP-Mover does immunoprecipitate upon IP with anti- myc antibody from co-
expressed HEK293T cell lysates. Co-expressed phospho-mutants of Mover-T13A, T64A, Y257F, T13A-T64A and 
T13-Y257A (L) with Mover-myc from HEK293T cell lysates were immunoprecipitated with sepharose beads coupled 
against anti-myc antibody and analyzed by SDS-PAGE and western blotting. Protein complexes on the western blot 
were detected by probing against anti-GFP and anti-Mover. Phospho-mimetic mutation at threonine 13 self-interacts 








3.4.3. Analysis of ERK phosphorylation site in Mover 
 
MAPK/ERK's (Mitogen Activated Protein Kinases/Extracellular signal Regulated 
Kinases) are protein kinases that are involved in intracellular signaling pathways. 











Fig.3.4.3. Mutation at the ERK phosphorylation site aa221 had no effect on 
the targeting of Mover to presynaptic sites Expression of C-terminally tagged full length 
Mover- mGFP with a point mutation at serine 221 to alanine (S221A-mGFP) in 14DIV cultured hippocampal neurons 
displayed a punctate fluorescence pattern along the axon. Puncta co-localizing with endogenous Synaptophysin are 
indicated with arrow heads. Higher magnification images of the inlay are shown in individual channels. Scale bar: 
10μm for grey panel and 2µm for small black panels (A). Bar graph representing the fluorescence intensities of 
synaptic puncta produced by Mover-mGFP and S221A-mGFP. No difference in the targeting of Mover-mGFP and 
S221A-mGFP mutant of Mover at the presynaptic sites was observed (B). Co-localization analysis representing the 
percentage of co-localized Mover or S221A puncta with Synaptophysin (C). No statistical difference either in their 
targeting or co-localization with Synaptophysin was observed between full length and S221A of Mover. t- test. Values 
represented as mean±SEM. 
 
I tested to see whether a mutation introduced into this site would have any effect in 
the presynaptic targeting of Mover. mGFP-tagged Mover with a point mutation at 
phosphorylation site 221 from serine to alanine was used for their expression in 
14DIV cultured neurons with full length Mover-mGFP as a positive control. Upon 
expression of S221A in cultured neurons, S221A displayed a punctate fluorescence 
pattern without any effect on the targeting of Mover to presynaptic sites (Fig.3.4.3; 
A). No difference in the targeting of S221A-mGFP at presynaptic sites (Fig 3.4.3; B) 
and percentage of co-localization with Synaptophysin was observed when compared 








3.5. Interaction of Mover with Calmodulin 
3.5.1. A point mutation at aa206 impairs presynaptic targeting and self-
interaction of Mover 
 
Calmodulin Target Database suggests that Mover has a predicted Calmodulin 
binding site of aa 206-218. The interaction of Calmodulin occurs through Calmodulin 
recognition motifs on target proteins and can be Ca2+ independent (such recognition 
motifs often include isoleucine and glutamine and thus called IQ motifs) or Ca2+ 
dependent. Canonical Ca2+dependent motifs are characterized by positively charged 
amphipathic helices predominated by hydrophobic residues at certain positions, i.e. 
at positions 1,5 and 10, or at positions 1,8 and 14 of the motif (Junge et al., 2004). 
Amino acids of 206-218 contain both an IQ motif and a predicted amphipathic helix 
with a positive charge (Fig. 3.5.1; A). In addition, there is data supporting that 
Mover binds to Calmodulin in the presence of calcium with pull-down assays using 
GST-fusion proteins and synaptosomal extract from rat brains (Saheeb Ahmed, ENI, 
Goettingen, unpublished). Interaction of Calmodulin requires the presence of 
hydrophobic residues on the target protein that could serve as an anchor for 
binding. Comparing Mover to the CaM-binding protein Munc13-1 (Junge et al., 
2004, Lipstein et al., 2013) reveals that Phenylalanine 206 qualifies as one such 
potential anchor. To test the role of the predicted CaM binding motif of Mover two 
full-length constructs were generated, one carrying a single point mutation (F206R), 
and one carrying the F206 mutation plus three additional mutations exchanging 
basic residues to acidic residues (Fig. 3.5.1; A). Four point mutations were 
introduced into the CaM recognition motif of Mover at phenylalanine to arginine at 
aa206 and lysine to glutamate at aa207, 215 and 219 (F206R, K207E, K215E and 

















Fig.3.5.1. A point mutation at aa206 impairs presynaptic targeting and self-
interaction of Mover. Amino acid sequence representing predicted Calmodulin binding site with the 
introduced point mutations. Amino acids with point mutations are denoted by '*' in red color and the exchanged amino 
acids in red (F) and green (E) (A).Expression of mGFP-tagged full length Mover, F206R mutant and a Mover mutant 
harboring four mutations in the predicted Calmodulin binding site (GFP-4-mut) displaying diffuse distribution along the 
axon in DIV14 cultured hippocampal neurons. Inlay shown as higher magnification images (left to right) of the 
construct (green), endogenous Synaptophysin (red) and merge image (along with   MAP2). Scale bar: 10μm for grey 
panel and 2µm for magnified images (B).GFP-Mover does immunoprecipitate upon IP with anti- myc antibody from 
co-expressed HEK293T cells lysates. Co-expressed GFP-F206R and GFP-4-Mut (four exchanged amino acids in the 
CaM recognition motif of Mover) with Mover-myc from HEK293T cell lysates were immunoprecipitated, analyzed by 
SDS-PAGE and western blotting. Protein complexes on the western blot were detected by probing against anti-GFP 
and anti-Mover. GFP-F206R and GFP-4-mut failed to immunoprecipitate with Mover-myc from Hek293T cell lysates 





Another construct of Mover with point mutation at aa206 alone was also generated 
and labeled as F206R and the one with four mutations as 4-mut. Strikingly, 
expression of either N-terminal GFP or C-terminal monomeric GFP tagged version of 
Mover-F206R and Mover with four mutations in the predicted Calmodulin site in 
14DIV cultured hippocampal neurons impaired the targeting of Mover to presynaptic 
terminals with a diffusely distributed pattern and a weak expression (Fig.3.5.1; B). 
Not only that, Mover-F206R and Mover with four mutations in the Calmodulin 
binding site also disrupt the self-interaction of Mover in Co-immunoprecipitation 
assay from HEK cell lysates (Fig.3.5.1; C ). 
 
3.5.2. Mover binds to Ca2+- Calmodulin 
 
We knew that Mover binds to Calmodulin in the presence of calcium (Saheeb 
Ahmed, ENI, Goettingen), unpublished data from pull-down experiments using GST-
fusion proteins and synaptosomal extracts from rat brain).This was further 
corroborated by co-immunoprecipitation experiments using GFP-Mover. The 
mutation at aa206 from phenylalanine to arginine in the predicted Calmodulin 
binding site impaired presynaptic targeting and self-interaction of Mover. Next I 
tested to see whether the point mutation at aa206 has any effect on Calmodulin 
binding. To do this, Hek293T cell lysates expressing N-terminal GFP-tagged F206R 
were incubated with purified recombinant Calmodulin in the presence of calcium. 
Anti-GFP antibody was used to pull down the protein complexes and analyzed by 
SDS-PAGE and western blotting.  
 
GFP-Mover binds to Calmodulin in the presence of Ca2+, whereas GFP does not (Fig 
3.5.2; A). Not only that the point mutation F206R is found to bind to Calmodulin in 
the presence of Ca2+, eliciting no effect of F206R on  Mover binding to Calmodulin 

















Fig.3.5.2 Mutation at aa206 does not affect the binding of Mover to 
Calmodulin.  GFP-Mover binds to Calmodulin. HEK293T cell lysates expressing GFP or GFP-Mover were 
incubated with recombinant purified CaM in the presence of 2mM Ca2+. Protein complexes were immunoprecipitated 
with monoclonal anti-GFP antibody, analyzed by SDS-PAGE and western blotting. GFP does not IP with CaM (A). 
Mutation at aa206 in the Calmodulin binding site had no effect on the binding of Mover to CalmodulinHEK293T cell 
lysates expressing GFP-F206R or GFP-Mover were incubated with recombinant purified CaM in the presence of 2mM 
Ca2+. Protein complexes were immunoprecipitated with anti-GFP antibody, analyzed by SDS-PAGE and western 





3.5.3. Mover does not inhibit Calmodulin in vitro 
 
Knock-down of Mover at the Calyx of Held synapse increases release probability (C. 
Körber, University of Heidelberg, thesis published online). Knock-down of 
Calmodulin in hippocampal neurons decreases release probability (Pang et al, 
2010). Therefore, Mover and Calmodulin may act in opposite directions regulating 
release probability, and Mover may inhibit Calmodulin in this scenario.  To test 
whether Mover inhibits the role of Calmodulin an assay for Calmodulin was 
established based on the following facts: One of the targets of CaM is Calcium-
Calmodulin dependent protein kinase II (CaMKII). Calmodulin is an EF hand 
member of calcium binding proteins that binds to four calcium ions. Ca2+- bound 




Fig.3.5.3. Mover does not inhibit Calmodulin in vitro. Purified GST-Mover and GST were 
used at varying concentrations and incubated with purified recombinant CaMKII and CaM in the presence of 2mM 
Ca2+. Following incubation, analyzed by SDS-PAGE and immunoblotted with antibodies against Mover, Calmodulin 






To this end, an in vitro biochemical assay was established and performed, keeping 
the concentration of CaMKII and Calmodulin constant but with varied concentrations 
of purified GST-Mover in the presence of calcium. This assay revealed no change in 
the phosphorylation of CaMKII both with GST-Mover and GST suggesting no effect 
on the phosphorylation of CaMKII by Mover-Calmodulin binding (Fig. 3.5.3; A). 
 
3.6. Overexpressing Mover causes a reduction in the recycling pool of 
vesicles. 
 
Knock-down of Mover at the Calyx of Held synapse increases release probability (C. 
Körber, University of Heidelberg, thesis published online), raising the possibility that 
Mover, and in particular overexpression of Mover, may decreases release. In order 
to investigate the role of Mover in synaptic vesicle recycling, a hypothesis was 
drawn from the preliminary unpublished data of Mover at the Calyx of Held. The 
hypothesis was to test whether over-expression of Mover decreases release 
probability (opposite to knock-down). To this end, recombinant mGFP tagged full-
length Mover, mGFP and mGFP tagged aa52-266 version of Mover that is found to 
be presynaptic from the targeting experiments were co-expressed with 
Synaptophysin -mOrange in cultured hippocampal neurons. The Synaptotagmin1 
antibody uptake assay (Syt1 assay) serves as readout for the extent of synaptic 
vesicle recycling. This is because Synaptotagmin1 antibody taken up by the synaptic 
vesicles during depolarization in cultured neurons is proportional to the total 
number of recycling vesicles. At 14DIV, a Synaptotagmin1 antibody uptake assay 
was performed, fixed and stained with respective secondary antibodies. Images 
were acquired using a 40X objective and Synaptotagmin1 fluorescence intensities 
were measured for Mover puncta positive for Synaptophysin mOrange. 
Synaptotagmin intensities measured for full length Mover and 52-266-mGFP 
revealed a statistically significant decrease in the total recycling pool of vesicles 
compared to mGFP (Fig.3.6; A and B), but no difference between full length and N-
terminal deletion mutant of aa51 was observed. This indicates that both 







         
B. Fig.3.6. Mover decreases the total 
pool of recyling vesicles. Co-expression of 
Mover-mGFP, 52-266-mGFP and mGFP with Synaptophysin 
mOrange (SyPhy mOrg) in cultured neurons. Mover-mGFP, 
52-266-mGFP and mGFP in green, Synaptophysin  mOrange 
in blue and Synaptotagmin in red. Images acquired after Syt1 
antibody uptake and analyzed for Synaptotagmin intensities 
(A). Scal bar 2µm (A). Bar graph representing the 
Synaptotagmin intensities for mGFP or Mover-mGFP or 52-
266-mGFPpuncta positive for Synaptophysin mOrange 
puncta, that show a decrease with respect to mGFP but the 
Syt1 intensities between full length and 52-266-mGFP remain 
unchanged. One Way AOVA with Bonferroni’s post hoc test. 





3.7. Generation of a Mover Knock-out mouse line 
 
Chimeric mice with modified Mover gene were bred with wild type mice and further 
with Rosa FLIP mice allowing removal of Frt-flanked neo expression cassette. At this 
stage the mice have a Mover gene that is flanked by loxp sites, hence called as ‘flox 
mice’. Heterozygous flox Mover mice were bred with Cre mice resulting in Cre 
positive heterozygous Mover mice, verified through genotyping. Finally the 
heterozygous Mover mice were inbred for the generation of global Mover knock-out 

















Fig. 3.7. Genotyping of Cre-lox Mover mouse population. Schematic representation of 
generation of Mover knock-out with the designed primers used for genotyping. Two primers (P3 and P4) were used to 
distinguish between wild type and recombined alleles of Mover. Primer pair 28816 and 28817 was used to identify 5' 
loxp sites. LoxP sites are indicated in by blue triangles and the neo cassette with green triangle. One of the LoxP site 
is in the untranslated region to the upstream of Mover gene (A). Schematic representation of PCR amplified loci for 
the identification of Mover knock-out. Three primers were used to distinguish (P4, E3001 and E4001) three alleles of 
Mover gene: wild type allele (+/+) heterozygous (+/-) and Cre-lox excised allele, KO (-/-). The sizes of the 
amplification products are 867bp for wild type (+/+), 697 bp (-/-) for knock-out and a double band with 867 and 697bp 
for heterozygous alleles (+/-) (B). Litter consisting of wild-type (+/+), heterozygous floxed (fl/+), and homozygous 
floxed mice (fl/fl) verified by PCR genotyping using two primers (P3 and P4) flanking the lower loxp site. A double 
band corresponds to heterozygote harboring a wildtype and floxed allele, single upper band represents the 
homozygous floxed mice and lower band a homozygous wild type animal (C1). Litter of a mouse population 
consisting of wild-type, heterozygous and knock-out alleles of Mover. A double band corresponds to heterozygote, a 
single lower band to knock-out and single upper band represents a wild-type allele (C2). 
 
3.7.1. Characterization of Mover knock-out mouse line 
 
Generating a conditional knock-out mouse line requires frequent genotyping at each 
stage of transgenic mouse populations. Genotyping requires establishing PCR 
protocols at each stage to identify the required transgene from mouse populations. 
 
Brain homogenates of 5-week old Mover heterozygous (+/-), homozygous flox (fl/fl) 
and global Mover knock-out mice were analyzed through SDS-PAGE and western 
blotting for the presence and absence of Mover along with unchanged 
Synaptophysin  and tubulin protein levels in the Mover knock-out (Fog. 3.7.1; A and 
B).  Cortical neuronal cultures were from Mover knock-out mice were verified for the 



















Fig 3.7.1. Characterization of Mover knock-out mouse line. Brain homogenates from 
heterozygous, flox Mover and Mover knock-out mice were analyzed through SDS-PAGE and western blot (top panel); 
and wild type mouse and rat, Mover knock-out mouse brains were homogenized and analyzed by SDS-PAGE and 
western blot (A).  Western blot analysis showing the absence of Mover from 5-week old mouse brain homogenate 
with Synaptophysin and β-3-tubulin as control (B). 14DIV cortical neurons from Wild type and knock-out Mover mice 







3.7.2. Phosphorylation  in presynaptic targeting of Mover 
 
Mutations introduced at predicted phosphorylation sites did not show any 
impairment in the presynaptic targeting of Mover in wild type rat cultures. This 









Fig.3.7.2. Point mutation at threonine 13 does not affect presynaptic 
targeting of Mover in Mover-deficient cultures. Expression of mGFP-tagged point full length 
Mover, 52-266-mGFP and the construct with a mutation at phosphorylation site threonine 13 (T13A) in 14DIV cultured 
hippocampal neurons showing a punctate pattern. Puncta co-localizing with Synaptophysin are indicated with arrow 
heads. Higher magnification images of the inlay are shown in individual channels (from left to right) - Over-expressed 
protein in green, Synaptophysin in red and a merge along with MAP2 in blue. Mover puncta co-localizing with 
Synaptophysin are pointed with arrow heads. Scale bar: 10μm for grey panel and 2µm for small black panels (A and 
B). 
depend on self-interaction as Mover is a self-interacting protein. Therefore mutation 
at phosphorylation site 13 has been over-expresses in Mover knock-out 
hippocampal cultures along with full length Mover and N-terminal deletion mutant of 
aa51.Full length Mover and N-terminal deletion mutant of Mover produced discrete 
punctae that are presynaptic as they co-localize with endogenous Synapsin (Fig. 
3.7.2;A). Mutating T13 did not impair presynaptic targeting of Mover even in Mover 
deficient cultures (Fig. 3.7.2; B). This could be due to the presence of this site (T13) 
within the variable N-terminal region of Mover that is unimportant for the 
presynaptic targeting and self-interaction of Mover. It will be interesting to test the 
expression of phosphorylation mutants at site 64 and 257 as they lie within the 







Mover is a vertebrate specific presynaptic protein of 266 amino acids. Structurally 
and functionally nothing is known about Mover. In the current work, I aimed to 
characterize functional domains of Mover underlying its cellular properties, including 
presynaptic targeting, self-interaction and phosphorylation, and to determine the 
role of Mover in presynaptic terminals. To this end, 
 
1. I used N-terminal or C-terminal GFP-tagged deletion mutants to identify the 
regions necessary for presynaptic targeting and self-interaction of Mover. This 
deletion analysis revealed different regions within the protein sequence 
including aa52-90, aa253-266, aa206 and 4 mutations in the predicted 
Calmodulin binding site to be necessary for presynaptic targeting and self-
interaction. 
2. I employed mutations changing threonine to alanine (to prevent 
phosphorylation) and mutations changing threonine to aspartate (to mimic 
phosphorylation) to investigate if phosphorylation may regulate the function 
of Mover. 
3. I used immunoprecipitatation assays to test the interaction of Mover with 
Calmodulin, Bassoon and Munc13. No interaction of Mover was found with 
Bassoon and Munc13 (Appendix 7.4. A& B) but Mover bound to Calmodulin in 
the presence of Ca2+ in vitro. 
4. I over-expressed full-length Mover and an N-terminal deletion mutant 
encoding amino acids 51-266 in cultured hippocampal neurons and found that 
both decreased the recycling pool of vesicles suggesting an inhibitory role for 
Mover in synaptic transmission. 
 
4.1. Tprg, a homologue of Mover 
 
Mover is found to share homology with Tprg (Transformation related protein 63 
regulated), a protein expressed in skin. Because of this homology, Mover is also 





vertebrate specific proteins that share 49% homology at the protein level. The 
former is associated with synaptic vesicles (Kremer et al., 2007) and the latter is 
predominantly expressed in skin with no expression detected in brain by PCR 
(Antonini et al., 2008). Expression of Mover-mGFP and Tprg-mGFP produces a 
punctate fluorescence pattern in primary hippocampal neurons that is typical of 
presynaptic targeting. These puncta have the same distribution as puncta created 
by expression of GFP-VAMP, a synaptic vesicle protein. Furthermore, the 
fluorescence puncta co-localize with endogenous Synaptophysin, indicating that 
they represent accumulation of the Mover and Tprg constructs at synapses. Antonini 
et al. (2008) did not detect Tprg mRNA in the brain, suggesting that Tprg is not 
expressed in brain tissue. However, antibodies that have been validated for western 
blot detection of endogenous Tprg are not available. At this point it cannot be 
excluded that Tprg is expressed in neurons at low levels. I found that recombinant 
Tprg accumulates in presynaptic terminals in transfected cultured neurons, 
indicating that the protein contains presynaptic targeting information. Tprg displays 
49 percent amino acid identity with Mover overall, and the identity is 51 percent in 
the region downstream of amino acid 69 of Mover. Further inspection of the 
sequence alignment reveals that the identity is evenly distributed across the entire 
protein. Thus, sequence comparison does not hint to any individual domain that 
might be particularly important for presynaptic accumulation of Mover and Tprg. It 
rather seems that the overall structure of Mover and Tprg mediates targeting. 
Measuring presynaptic targeting of Mover-mGFP and Tprg-mGFP revealed that 
recombinant Mover is enriched twice the level of recombinant Tprg at presynaptic 
sites, but the sequence comparison does not hint to any amino acid sequences that 
could account for this difference in targeting efficacy. Since I cannot exclude that 
Tprg is expressed in the brain it was important to know if Mover can interact with 
Tprg. No interaction of recombinant Mover with recombinant Tprg is observed with 
co-immunoprecipitation experiments indicating a role for Mover by itself in the 
brain. Importantly, in overexpression experiments carried out in Mover knockout 
mice it is unlikely that recombinant Mover binds to endogenous Tprg, if it is 
expressed at all. Therefore Mover and Tprg are two different proteins that may have 
different roles to play. In future experiments; it would be interesting to test the 





also by immunofluoroscence on neuronal cultures. In addition, to see if Mover and 
Tprg are in different set of synapses or brain regions, and to see if Tprg is 
upregulated in Mover knockouts. 
 
4.2. Presynaptic targeting of Mover 
 
Not much is known about the targeting of proteins to presynaptic sites. Predicted 
domains within protein sequence and structure would provide an insight into its 
functional role. Mover is a vertebrate specific presynaptic protein that has been 
identified as a binding partner of C-terminal region of Bassoon (Kremer et al., 
2007). It has been further detected as a synaptic vesicle associated protein 30 
(SVAP30) in a proteomics screen for synaptic vesicles (Burre et al., 2006). Absence 
of transmembrane domains and association of Mover to synaptic vesicles indicate 
that Mover is a peripheral membrane protein associated with SVs. This observation 
was confirmed by several assays including membrane floatation assay, TritonX-100 
treatment, carbonate stripping and immunogold labeling of SVs (Ahmed et al., 
2013). Several lines of evidence conclude that Mover is a peripheral membrane 
protein associated with SVs.  
 
Structurally and functionally, little is known about Mover. Mover has no predicted 
homology domains except for a HSac2 domain spanning amino acids 53-163 and a 
predicted Calmodulin binding domain including amino acids 206-218. HSac2 belongs 
to family of inositol phosphatases and functions as inositol polyphosphate 5-
phosphatase that are involved in several functions like synaptic vesicle recycling, 
synaptic vesicle trafficking and actin polymerization. Database analysis suggests 
that Mover gene is alternatively spliced producing two isoforms, a long form 
harboring Exons 1-4 and a short form lacking Exon2 (93-151). 
 
Recombinant full length Mover is targeted to presynaptic terminals in cultured 
hippocampal neurons. But the regions or domains of Mover necessary for targeting 
to presynaptic terminals are unknown. In this study, regions required for 





Monomeric GFP (mGFP) tagged versions of deletion mutants have been used to 
identify the domains of Mover required for localization to presynaptic terminals. A 
similar strategy has been used to study two other presynaptic proteins, α-synuclein 
and Synapsin (Yang et al., 2010; Gilter et al., 2004). Synapsins are the most 
abundant phosphoproteins present on synaptic vesicles and are involved in multiple 
functions of synaptic vesicle cycle. Domains B, C and E of Synapsin Ia are required 
binding sites involved in targeting of Synapsin Ia to presynaptic terminals. This 
observation indicates that multiple binding sites are required for targeting of 
Synapsin Ia to presynaptic terminals (Gilter et al., 2004). α-synuclein is a 
vertebrate specific presynaptic protein regulating neurotransmission in 
dopaminergic neurons. α-synuclein protein is unstructured with an amphipathic 
lysine rich N-terminus adopting a α-helical secondary structure upon binding to 
phospholipid membranes. Using deletion mutants of α- Synuclein, it was found that 
the N-terminal helix binding loop is necessary for the targeting of α-Synuclein to 
presynaptic sites (Yang et al., 2010). Mover as such has no predicted domains like 
α-synuclein or Synapsins and the recruitment of Mover to presynaptic sites is 
unknown. Similar to Synapsins, different sites have been found for the localization 
of Mover to presynaptic terminals in the current study and are discussed as follows: 
 
The presence of either N-terminal GFP (Appendix 7.1 & 7.2) or C-terminal mGFP tag 
to the deletion mutants did not have any effect on their targeting to presynaptic 
sites. However, a full-length version of Mover with an N-terminal GFP tag 
aggregated upon expression in neurons. The study therefore focused on full-length 
Mover with C-terminal tags. All deletion constructs were produced with N-terminal 
and C-terminal tags, with no difference in targeting. Monomeric GFP tagged full 
length Mover and the N-terminal deletion mutant of aa51 were found to produce 
punctae along the axon that synaptic as they co-localize with endogenous 
Synaptophysin. Co-localization analysis with endogenous Synaptophysin shows no 
significant difference in the localization of full length Mover and the N-terminal 
deletion mutant to presynaptic terminals. In addition, the full length Mover and the 
N-terminal deletion mutant of aa51 were no different in their targeting to 
presynaptic terminals. These data suggest that Mover can still be targeted to 





to produce an unstructured conformation. This N-terminal region of Mover contains 
several parts where sequences are less well conserved across species than in the 
remaining parts of Mover. Thus, the N-terminal area of Mover may be relevant for 
other functions than a key property such as synaptic accumulation. 
 
A construct lacking the sequences encoded by exon2 was generated to mimic a 
short splice isoform of Mover in which exon 2 is missing. This construct did not 
target to synapses in cultured neurons. A cDNA encoding such a splice isoform is 
found in data base searches. Interestingly, if such a splice isoform exists in the 
brain it is probably not synaptic. A construct encoding the HSac2 homology domain 
of Mover did not target to synapses, suggesting that the HSac2 domain is not 
sufficient for presynaptic targeting. In addition, several Mover constructs including 
the sequence encoded by exon2 (e.g. Mover-F206R-mGFP) do not target to 
presynaptic terminals. Thus, these two domains do not by themselves carry 
sufficient targeting information. However, both regions are required, because 
deleting parts of these regions impaired targeting. Deletion of N-terminal aa1-90 
and the C-terminal 13 aa (253-266) impaired presynaptic targeting of Mover, 
generating a diffuse distribution along the axon. Thus, N-terminal aa51-90, a C-
terminal region of aa13, a central exon2 region, and regions in the HSac2 domain of 
Mover are all necessary for the targeting of Mover to presynaptic terminals. These 
regions are widely distributed across Mover, suggesting that the entire protein 
(except for the N-terminal 51 amino acids) has to be present to adopt a functional 
conformation. The disruption of presynaptic targeting and the weak expression of 
these deletion mutants could be due to lack of proper folding or conformational 
changes, leading to protein degradation. 
 
Not only that, a construct with four point mutations introduced into the predicted 
Calmodulin binding site also impaired presynaptic localization of Mover. Strikingly, a 
point mutation at aa206 from phenylalanine to arginine in the predicted Calmodulin 
binding site completely disrupts the localization of Mover to presynaptic terminals. 
Although different sites distributed over Mover protein sequence were found to be 
required for Mover to undergo presynaptic targeting, a single amino acid at 206 is 





required for presynaptic targeting of Mover can be attributed to the structure of 
Mover which is dominated by loops and possibly account for a highly dynamic 
structure prone to destabilization (PLYMOL prediction tool).Any change in the Mover 
protein structure except the N-terminal aa51 could disrupt the targeting to 
presynaptic terminals. 
 
4.3. Role of Dimerization/ oligomerization in the presynaptic 
targeting of Mover 
 
Dimerization/oligomerization of proteins is shown to be necessary for the targeting 
of presynaptic proteins like Synapsins, Bassoon, GAD65/GAD2and GAD67/GAD1 
(Gitler et al., 2004; Maas et al., 2012; Kanaani et al., 2010). Very little is known 
about the targeting of proteins with no transmembrane regions. Multiple sites within 
the Bassoon Golgi binding region have been identified to undergo dimerization in 
addition to an oligomerization domain between aa2088-2563. A deletion mutant 
with aa1692-3263 harboring the oligomerization domain is found to be targeted to 
presynaptic sites but the expression of oligomerization domain alone disrupts the 
targeting of Bassoon in cultured hippocampal neurons (Dresbach et al., 2003; Maas 
et al., 2012). Synapsins are the peripheral membrane phosphoproteins associated 
with synaptic vesicles. Dimerization of Synapsin isoforms (Ia, IIa, and IIIa) allows 
their targeting to presynaptic sites. Heterodimerization with other isoforms of 
Synapsins is required for Synapsin Ib to be targeted to presynaptic terminals in 
cultured neurons (Gitler et al., 2004). Similarly, the region within the N-terminal 60 
amino acids contains the information necessary for the presynaptic targeting of a 
peripheral membrane protein, GAD65 (Kanaani et al., 2002), and GAD65 can recruit 
the isoform GAD67 to synapses by hetero-dimerization (Kanaani et al., 2010). In 
most of the proteins, a combination of several areas distributed across the proteins 
and dimerization are involved in presynaptic targeting, but no consensus sequence 
seems to exist. Interestingly, the current study identifies multiple regions 
distributed over the Mover protein sequence are necessary for the self-association 






Yeast 2-hybrid assay suggests that full-length Mover undergoes self-interaction. The 
data that full length Mover undergoes self-interaction is further corroborated by a 
co-immunoprecipitation assay using two differently tagged recombinant Mover 
constructs in this study. Applying this assay, I next tested the regions required for 
self-interaction of Mover and compared them with the regions required for 
presynaptic targeting. 
 
All the deletion mutants except for recombinant full length Mover and the N-
terminal deletion of aa51 were found to self-interact forming a dimer (or oligomer) 
in vitro. The N-terminal deletion construct Mover-91-266-mGFP, the Exon2 deletion 
mutant, and further N- & C-terminal deletion constructs (aa53-163 and aa52-253) 
failed to dimerize, indicating that all the regions of Mover except the N-terminal 51 
amino acids are required for the self-association of Mover. Not only that, four point 
mutations introduced into the predicted Calmodulin binding site also  disrupt the 
dimerization of Mover. Interestingly, a single point mutation at aa206 was sufficient 
to completely disrupt the self-interaction of Mover, thus providing a link between 
the self-interaction and presynaptic targeting of Mover. 
 
Overall, all the deletion mutants that impair presynaptic targeting also failed to 
dimerize in vitro. In particular, sites of aa52-aa90 and aa253-aa266, central Exon2 
region, HSac2 domain, aa206 and the 4-mutations in the predicted Calmodulin 
binding site are required for Mover to undergo self-interaction and targeting to 
presynaptic terminals. Most importantly, a single amino acid at 206 was sufficient 
for Mover to undergo self-interaction and presynaptic targeting. Thus, regions 
necessary for the self-association and presynaptic localization of Mover are 
distributed over the entire Mover protein sequence. 
 
4.4. Role of phosphorylation in the presynaptic targeting of Mover 
 
Phosphorylation of proteins plays an important role in both pre-and post-synaptic 
plasticity. This is achieved through presynaptic modulation of neurotransmitter 





in multiple steps of synaptic vesicle cycling are found to be regulated by 
phosphorylation (refer to Fig 1.3). One best-studied protein is the Synapsin. 
Phosphorylation of Synapsin results in their dissociation from SVs in the reserve 
pool and mobilizing SVs to the active zone for exocytosis (Hosaka et al., 1999). 
Mass spectrometry study of presynaptic proteins detected threonine phosphorylation 
at amino acid 13of Mover (Munton et al., 2007). Bioinformatical analysis also 
suggested additional predicted phosphorylation sites at aa14 (Serine), aa64 
(Threonine) and aa 257 (Tyrosine). Threonine 13 is interesting because Mover 
phosphorylated at T13 is associated with SVs (Ahmed et al., 2013). Phosphorylation 
sites T64 (aa51-266) and Y257 (aa52-253) were also of interest as they lie within 
the regions required for self-interaction and targeting of Mover 
I employed the expression of mutated forms of the Mover protein that were 
rendered non-phosphorylatable by changing threonine to alanine or tyrosine to 
phenylalanine, and phosphomimetic mutant where threonine was changed to 
aspartate. Each construct included one of the following mutations: a single point 
mutation introduced at threonine 13 or 64 (T13A, T64A), or tyrosine 257 (Y257F), 
double mutations at threonine 13 and 64(T13A-T64A) or threonine 13 and tyrosine 
257 (T13A-Y257F), and a phosphomimetic mutation at threonine 13 to aspartate 
(T13D). Each of these constructs showed discrete punctae along the axon that co-
localized with endogenous Synaptophysin, indicating that they accumulated at 
synapses. Co-localization analysis with endogenous Synaptophysin did not show any 
statistical difference between phospho-mutants of Mover and full length Mover. No 
statistical difference in the presynaptic targeting capacity between full length Mover 
and either the single or double phospho-mutants of Mover was observed. It is 
possible that over-expressed phospho-mutants bind to endogenous Mover protein 
present in cultured rat neurons and therefore are recruited to presynaptic sites. 
Hence it would be interesting to test the expression of either single or double 
phospho-mutants of Mover in Mover-deficient cultures. Alternatively, 






Co-immunoprecipitation experiments with all the phospho-mutants showed pull-
down of all of the mGFP-tagged phospho-mutants of Mover with Mover-myc, 
indicating self-interaction. Therefore, the constructs may be deficient in presynaptic 
targeting but are recruited to synapses by the intact endogenous Mover protein 
present in cultured rat neurons. To test if the phosphorylation mutants still target to 
synapses in the absence of endogenous Mover, I expressed a phospho-mutant T13A 
in Mover knockout cultures. Unexpectedly, phospho-mutant T13A displayed a 
punctate fluorescence similar to full length and N-terminal deletion mutant. The 
puncta were synaptic as they co-localize with endogenous Synapsin. This could be 
due to the fact that the phosphorylation site at T13 lies with the N-terminal region 
of aa51 that is not required for Mover to undergo self-interaction and presynaptic 
targeting. Hence it would be interesting to see the phenotype of phosphorylation 
sites at aaT64 and Y257 as they are located within the sites necessary for the self-
association and targeting of Mover (aa52-90 and c-terminal aa13). Future 
experiments would be to see how these two mutants (T64A and Y257A) either 
singly or double behave and this would provide a link to the role of phosphorylation 
in the presynaptic targeting of Mover. 
 
Mover is lost from synaptic vesicles when synaptosomal fractions were incubated 
with bacterial lambda-phosphatase (Ahmed et al., 2013). This observation raised 
the possibility that the phosphorylation of Mover regulates its association with 
synaptic vesicles. If future experiments reveal that none of the predicted 
phosphorylation sites of Mover are required for targeting, one may conclude that 
phosphorylation of a direct or indirect binding partner of Mover is required for the 
association of Mover with presynaptic terminals. One possibility is that Mover binds 
to phosphorylated Bassoon (Collins et al., 2005; Schröder et al., 2013) 
 
4.5. Interacting partners of Mover 
 
Identifying interacting partners of Mover could provide a link to study the role and 
function of Mover in neurotransmitter release. The N-terminal region of Munc13-1 





region of Bassoon (aa3601-3820) (Wang et al., 2009) and Calmodulin (Junge et al., 
2004). Interestingly, Mover interacts with amino acids 3263-3938 of Bassoon in a 
yeast-2-hybrid assay, i.e. in the same region where Munc13 binds to Bassoon 
(Kremer et al., 2007). Knock-down of Mover at Calyx of Held synapse increases 
release probability and Ca2+ sensitivity of release without affecting the size of RRP 
(Körber C, published thesis). In contrast, knock-down of Calmodulin showed a 
decrease in release probability with unaltered RRP (Pang et al. 2010). I detected 
binding of Mover to Calmodulin with co-immunoprecipitation of recombinant protein. 
In addition, recombinant Calmodulin pulls down endogenous Mover from rat brain 
synaptosomes in the presence of Ca2+ (Saheeb Ahmed, unpublished data). 
Database analysis of Mover predicts a Calmodulin binding site between aa206-218. 
Together with these data, a point mutation was introduced at the hydrophobic 
phenylalanine residue of the Calmodulin binding site (206) to arginine to block 
Calmodulin binding. A similar mutagenesis strategy is published for Munc13-1, 
where a tryptophan to Arginine mutation blocked Calmodulin binding with no effect 
on the structural properties of Munc13-1 (Junge et al., 2004). In contrast to this 
study, no effect was observed on the binding of Mover to Calmodulin when 
phenylalanine 206 is mutated, but homomeric interaction and presynaptic targeting 
were abolished, indicating a profound effect on the structure and integrity of Mover. 
These data also indicate that monomeric and dimeric/ oligomeric Mover bind to 
Calmodulin, but only the dimerization / oligomerization – competent Mover is stable 
and accumulates at synapses in cultured neurons. Thus, binding of Mover to 
Calmodulin does not mediate targeting to presynaptic sites. 
 
Because knock-down of Mover and Calmodulin individually have opposing effects on 
release probability, we assumed that Mover may regulate release probability by 
inhibiting Calmodulin. Inhibition of Calmodulin may reduce the action of Calmodulin 
targets such as CamKII (Ca2+-Calmodulin dependent protein kinase II) (Popoli et 
al., 1993), Munc13-1  (Junge et al., 2004). However, in our assay, we found no 
effect of Mover on the CaM-dependent phosphorylation of CaMKII. It is possible that 
Mover may inhibit the action of Calmodulin on Munc13-1. Next, I tested if Mover 
inhibits Calmodulin and affects Munc13-1 interaction; preliminary experiments show 





Munc13-1. Although no interaction of Mover with Munc13-1 was found in co-
immunoprecipitation experiments (Appendix 7.4, B). 
 
4.6.   Role of Mover in synaptic vesicle recycling 
 
Knockdown of Mover at the Calyx of Held increases release probability, short-term 
depression and recovery from depression (Körber reference). Thus, the role of 
Mover may be to inhibit these events. To test if increased Mover levels affect the 
synaptic vesicle cycle, I employed a synaptotagmin1 antibody uptake assay. In this 
assay, antibodies against the intravascular domain of synaptotagmin are taken up 
into recycling synaptic vesicles during endocytosis after induced exocytosis. Because 
the N-terminal deletion mutant Mover-52-266-mGFP behaves like full length Mover 
in its cellular properties (targeting and dimerization), it was interesting to test if this 
deletion mutant also behaved like full-length Mover in the recycling assay. 
Measuring Synaptotagmin uptake intensities for the Mover-mGFP puncta positive for 
Synaptophysin-mOrange showed a robust decrease in the total pool of recycling 
vesicles compared to mGFP. The same decrease was observed withMover-52-266-
mGFP compared to mGFP, but no significant difference was observed between full 
length Mover and Mover-52-266-mGFP, suggesting that Mover lacking the N-
terminal 51 amino acids may be sufficient for Mover to regulate the synaptic vesicle 
cycle.  
 
The reduction in synaptic vesicle recycling produced by Mover-1-266-mGFP and 
Mover-52-266-mGFP is due to a reduction in the Ca2+-dependent exocytosis, in 
endocytosis, or in replenishment of the releasable pool of vesicles. One possibility is 
that Mover inhibits one or more of these steps by inhibiting the action of 
Calmodulin. Calmodulin regulates multiple presynaptic events, including release 
probability, calcium channel inactivation, endocytosis, RRP replenishment and 
recovery from depression (Pang et al, 2010, Mochida et al, 2011, Lipstein et al, 
2013, Rehger et al, 2015). Mover and Calmodulin act in opposite directions, raising 
the possibility that Mover inhibits Calmodulin. I tested if Mover inhibits the action of 





Mover selectively inhibits the interaction of Calmodulin with Munc13. This interaction 
enhances replenishment of the RRP (Junge et al., 2004; Lipstein et al., 2013). 
 
A reduction in the total pool of recycling vesicles could also result from interactions 
with proteins other than Calmodulin. For example, Tomosyn, a syntaxin binding 
protein is known to decrease synaptic transmission and release probability of 
vesicles by priming of synaptic vesicles and interfering with the SNARE complex 
formation, the essential machinery of vesicle fusion thereby inhibiting 
neurotransmitter release (Barak et al., 2010).Further knowledge about binding 
partners of Mover is needed to unravel the molecular mechanisms underlying its 
inhibitory role. In particular, a mutant construct that fails to bind to Calmodulin but 
targets to presynaptic terminals would help address these questions. 
 
In summary, self-interaction of Mover is required for Mover to undergo targeting to 
presynaptic terminals. Sites distributed over the Mover protein sequence mediate 
both self-interaction and targeting of Mover to presynaptic terminals. Mutations 
introduced into the predicted phosphorylation site at T13 had no effect on the 
targeting of Mover but biochemical data suggests that phosphorylation is associated 
with binding of Mover to SVs (Ahmed et al, 2013). Phosphorylation of Mover may 
switch the transition of SVs from the reserve pool to active zones, where Mover 
binds to a C-terminal region of Bassoon. The C-terminal region of Bassoon acts as a 
common interaction region for the Munc13-1-CaM complex (amino acids 3601-
3820; Wang et al, 2009) and Mover (amino acids 3263-3938;Kremer et al, 
2007).Mover in turn also binds to Ca2+-Calmodulin and inhibits SV recycling (this 
study). Mover may be present on SVs as a dimer, and one could speculate that one 
Mover copy would bind to Bassoon and the other to Calmodulin. This could inhibit 
the Munc13-1-CaM interaction, down regulating priming of synaptic vesicles by 
Munc13s resulting in reduced SV replenishment. Alternatively, Mover may regulate 
the interaction of Bassoon with voltage gated calcium channels and increase the 
distance between docked synaptic vesicles and sites of calcium influx, thus reducing 







4.7. Future perspectives 
 
In the future, it would be interesting to  
 
1. test the expression of Tprg in the brain by western blotting using brain 
homogenates from wild type and Mover knock-out mice and also by 
immunofluoroscence on cultured neurons from wild type and Mover deficient 
mice.  
 
2. test if Mover undergoes dimerization/oligomerization in the presence of Ca2+ 
using co-immunoprecipitation assay. 
 
3. test the role of phosphorylation in the presynaptic targeting and synaptic 
vesicle recycling. This would allow identifying a role for phosphorylation of 
Mover. 
 
4. test whether the deletion mutant harboring 4 exchanges in the predicted 
Calmodulin binding site affects the binding of Mover to Calmodulin and 
whether Mover affects the Munc13-1-Calmdulin interaction  
 
5. unravel the role of Mover in synaptic vesicle recycling using wild type and 
Mover deficient cultures.  
 
6. determine the expression levels of presynaptic proteins in Mover knock-out 
cultures as preliminary results from Mover knock-out cultures reveal a 













Synapses are asymmetric intercellular junctions. Targeting of synaptic vesicles to 
presynaptic sites is one of the most intricate examples of polarized trafficking and 
selective protein accumulation. Little is known about amino acid sequences or 
structural determinants mediating presynaptic targeting of synaptic vesicle proteins.  
Mover / TPRGL / SVAP30 is a 266 amino acid protein associated with synaptic 
vesicles as a peripheral membrane protein.  Structurally nothing is known about 
Mover except for the presence of a predicted HSac2 domain, phosphorylation sites 
and a predicted Calmodulin binding site. The regions or amino acid sequences 
mediating targeting of Mover to presynaptic terminals are unknown. 
 
I found that dimerization of Mover allows the targeting of Mover to synaptic 
vesicles. Sites widely distributed over large parts of Mover mediate both self-
interaction and presynaptic targeting of Mover. The HSac2 homology domain of 
Mover and the part encoded by the alternatively spliced exon 2 are required but not 
sufficient for targeting. Despite strong homomerization Mover does not 
heterodimerize with its paralogue TPRG. Mover is a novel binding partner for 
Ca2+/Calmodulin but this interaction does not mediate the presynaptic targeting of 
Mover, because a point mutated variant of Mover that still binds to Calmodulin is 
deficient for dimerization and targeting. Mutations introduced into the predicted 
phosphorylation sites had no effect on dimerization and targeting of Mover 
suggesting a function for phosphorylation other than targeting. Over-expression of 
Mover reduces the pool of recycling vesicles suggesting an inhibitory role in 
neurotransmitter release. A Mover knockout mouse was generated to explore the 
role of Mover for presynaptic function, and studies investigating synaptic vesicle 
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Fig.7.1. GFP-33-266 andGFP-52-266are accumulated at presynaptic 
sites. Expression of N-terminal GFP-tagged33-266and 52-266 showing a punctate fluorescence pattern 
in 14DIV cultured hippocampal neurons. Inlay is shown as higher magnification images (left to right) of the 
construct(green), endogenous Synaptophysin (red) and merge (along with   MAP2).Arrow heads indicate 








Fig.7.2. Localization of N-terminal GFP-tagged deletion mutants of 
Mover to presynaptic sites. Expression of N-terminal GFP-tagged1-90, 1-180, Δ93-151, 53-
163, 91-266, 52-253 and F206R showing diffuse distribution in 14DIV cultured hippocampal neurons. Green 








A.       B. 
    
Fig.7.3. Recombinant Mover reduces the levels of either Calmodulin or 
Munc13-1 in vitro. Munc13-1-EGFP from Hek293T cell lysates is immunoprecipitated using mouse  
monoclonal anti-GFP antibody. Munc13-1 and CaM were immunoprecipitated upon IP with anti-GFP-antibody. 
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Fig.7.4. Co-immunoprecipitation experiments of Mover with Bassoon and 
Munc13-1. Mover-myc does not bind to GFP-Bsn-3584-3938 in co-immunoprecipitation experiments. Mover-myc 
from Hek cell lysates was immunoprecipitated using mouse monoclonal antibody against myc tag. GFP-Bsn-3584-
3938 does not immunoprecipitate upon IP with Mover-myc (A). Munc13-EGFP co-expressed with Mover-myc does 
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